

CURRICULUM VITAE

DOMENIC JOSEPH REDA, PH.D.

August 11, 2023

CURRENT POSITIONS:

- 2015 - present Research Associate Professor
Northwestern University Medical Center
Feinberg School of Medicine
Department of Preventive Medicine
- 2013 - present Research Associate Professor
University of Illinois at Chicago
School of Public Health
Department of Epidemiology and Biostatistics
- 2002 - 2013 Research Assistant Professor
University of Illinois at Chicago

PREVIOUS EXPERIENCE:

- 1977 USG Corporation - Operations Research Analyst and Scientific Programmer
- 1978 University of Illinois Medical Center, School of Public Health, Department of
Environmental and Occupational Health Sciences - Statistical Programmer/
Statistician
- 1979 Cook County Hospital, Division of Occupational Medicine - Biostatistician/
Programmer
- 1980 University of Illinois Medical Center, School of Public Health, Department of
Epidemiology and Biometry - Research Associate
- 1980 Department of Veterans Affairs, Hines Cooperative Studies Program Coordinat-
ing Center
Statistical Programmer (1980)
Biostatistician (1981)
Senior Biostatistician (1986)
Assistant Director (1993)
Associate Director (1998)
Acting Director (2002)
Director (2007-2020)

EDUCATION:

- 1974 University of Illinois at Chicago - B.S. (Mathematics and Computer Science)
- 1976 Purdue University - M.S. (Applied Statistics)
- 2001 University of Illinois at Chicago - Ph.D. (Biostatistics)

HONORS AND AWARDS:

- 1970 James Scholar, University of Illinois honors society
- 1971 Phi Eta Sigma honors fraternity
- 1976 Doctoral Fellowship, Ohio State University Department of Biostatistics
- 2001 William Haenszel Research Award, University of Illinois at Chicago Department of Epidemiology and Biostatistics
- 2006 Chapter Service Award, Northeastern Illinois Chapter, American Statistical Association
- 2007 Outstanding Alumnus, Purdue University Department of Statistics
- 2009 Fellow, American Statistical Association
- 2012 Fellow, Society for Clinical Trials
- 2014 Teaching Excellence Award, Feinberg School of Medicine, Northwestern University

CLINICAL RESEARCH ACTIVITIES:

1. CSP #127: Hydrochlorothiazide vs. Propranolol for Monotherapy of Hypertension (1980) – funded by VA
2. CSP #213: Treatment of Mild Hypertension in the Aged (1981) - funded by VA
3. CSP #232: Reanalysis of the Mild Hypertension Feasibility Trial Data (1982) – funded by VA
4. CSP #246: Treatment of Benign Prostatic Hyperplasia in Elderly Men (1982) – funded by VA
5. CSP #290: Monotherapy of Hypertension (1984) – funded by VA
6. CSP #341: Sulfasalazine vs. Placebo in the Treatment of Seronegative Spondyloarthropathies (1988) – funded by VA, Kabi Pharmacia
7. CSP #369: Prevention of End Stage Renal Disease (1990)
8. CSP #392: A Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Erythropoietin in Dialysis Patients (1991) – funded by VA, Amgen

9. CSP #399: The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation (1992) – funded by VA, Wyeth-Ayerst, Berlex
10. A Comprehensive System for Quality Improvement in Ambulatory Care (1992) – funded by VA
11. CSP #411: The Coronary Artery Revascularization Prophylaxis (CARP) Trial (1993) – funded by VA
12. CSP #426: Percutaneous Endarterectomy, the Goal for Atherectomy Successfully Guided by UltraSound (PEGASUS) (1994)
13. CSP #438: Prophylaxis of Medical Patients for Thromboembolism Study (1996) – funded by VA
14. CSP #456: Tension Free Inguinal Hernia Repair: Comparison of Open and Laparoscopic Surgical Techniques (1996) – funded by VA
15. CSP #444: Telemedicine for the Management of Diabetic Retinopathy (1997)
16. CSP #458: National Health Survey of Gulf War Era Veterans and Their Families (1997) – funded by VA
17. Exercise Effect on Aerobic Capacity and QOL in Heart Failure (1997) – funded by VA
18. CSP #462: Comparison of a COX-2 Inhibitor, a NSAID and Acetaminophen in the Treatment of Knee Osteoarthritis (1998)
19. CSP #465: Glycemic Control and Complications in Diabetes Mellitus Type 2 (1998) – funded by VA
20. CSP #468: A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease (1998) – funded by VA, NINDS, Medtronic
21. Comparison of Glucosamine, Chondroitin Sulfate, Combination Glucosamine Plus Chondroitin Sulfate, a COX-2 Inhibitor and Placebo in the Treatment of Knee Pain Due to Osteoarthritis. (1998) – funded by NCCAM, NIAMS.
22. A Comparison of Open Tension-Free Repair to Watchful Waiting for the Treatment of Inguinal Hernia (1998) – funded by AHRQ
23. CSP #474: Radial Artery vs. Saphenous Vein Grafts in Coronary Artery Bypass Surgery (1999) – funded by VA
24. Effect of Ventilation-Feedback Training on Exercise Performance in COPD (1999) – funded by VA
25. Polestriding Exercise and Vitamin E for Management of Peripheral Vascular Disease (2000) – funded by VA
26. Cost and Effectiveness of End Stage Renal Disease Care (2000) – funded by VA
27. A Randomized Controlled Trial of Male Circumcision to Reduce HIV Incidence in Kenya (2000) – funded by NIAIDS
28. CSP #418A: Long Term Follow-up of Patients in the NIDCD/VA Hearing Aid Clinical Trial (2001) – funded by VA, NIDCD
29. An Educational Intervention to Improve Calcium Intake and Bone Health in Adolescent Girls (2001) – funded by Department of Agriculture
30. Home-Based Exercise and Nutrition Program for Pain Control in Overweight Elderly Osteoarthritics – funded by VA (2002)
31. An Open-Label Study of Capecitabine for the Treatment of Hormone Refractory Prostate Cancer (2002) – funded by Roche Laboratories

32. Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial (2002) – funded by VA
33. Ventral Incisional Hernia Repair: Comparison of Laparoscopic and Open Repair with Mesh (2002) – funded by VA
34. CSP #502: A Phase III Study to Test the Efficacy of GM-CSF to Reduce the Severity and Duration of Mucositis Associated with Concomitant Chemoradiation Therapy in Head and Neck Cancer Patients (2003)
35. A Randomized, Double Blind, Placebo Controlled Trial of Intravenous Zoledronic Acid to Prevent Osteoporosis in Men Undergoing Androgen Deprivation Therapy in the VA Population (2003) – funded by Novartis
36. Sudden Hearing Loss Multicenter Treatment Trial (2003) – funded by NIDCD
37. Evaluation of a New Outpatient Low Vision Program for Legally Blind Veterans (2004) – funded by VA
38. Inguinal Hernia Trial Registry (2004) – funded by American College of Surgeons
39. Stem Cell Therapy as Adjunct to Coronary Artery Revascularization - funded by VA (2004)
40. CSP #550: Outcomes and an Economic Analysis of Store and Forward Teledermatology (2004). Revised and submitted to VA Health Services R&D (2007) – funded by VA
41. CSP #557: VA Coronary Artery Revascularization in Diabetes Study (2004) – funded by VA
42. Evaluation of Stress Response Systems in Gulf War Veterans with CMI – funded by VA (2005)
43. Chronic Kidney Disease Care: Quality Enhancement with State-of-the-Art Technology (2005)
44. Is Systemic Inflammation a Mechanism of Functional Impairment in COPD? – funded by VA (2005)
45. Polestriding versus Walking for PAD Rehabilitation – funded by NINR (2005)
46. CSP #564: Prophylaxis versus Preemptive Therapy for CMV in Liver Transplant Recipients (2005)
47. CSP #567 Clinical Demonstration of an EEG Brain-Computer Interface for ALS Patients (2007) – funded by VA
48. CSP #465F: Glycemic Control and Complications in Diabetes Mellitus Type 2 Follow-up Study (2007) – funded by VA
49. CSP #468F: A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson’s Disease Follow-up Study (2008) – funded by VA, NINDS
50. CCTA #0001: Rivastigmine Patch in Veterans with Cognitive Impairment Following TBI (2008) –funded by VA
51. CCTA #0002: Endothelial Progenitor Cell Mobilization with Intensive Lipid Lowering – funded by VA (2008)
52. Low Vision Intervention Trial II – funded by VA (2008)
53. Randomized Controlled Trial of Voice Therapy on Children with Vocal Nodules – funded by NIDCD (2009)
54. CCTA #0003: RCT of Water Infusion vs. Air Insufflation for Screening & Surveillance Colonoscopy (2009)

55. CCTA #0004: Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone (2009) – funded by VA
56. CCTA #0005: Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (2009) – approved for funding by VA
57. Intratympanic Steroids for Meniere’s Disease (2009)
58. CSP #584 – Minimizing Acid Suppression as a Strategy to Prevent Infections in Veterans with Cirrhosis (2010)
59. CSP #585 - Gulf War Illness Genome-wide Association Study (2010)
60. CCTA #0006 - Safety and Efficacy of Nopicastat in the Treatment of Cocaine Dependence (2010)
61. CCTA #0007 - An RCT of Acceptance and Commitment Therapy – Alternative PTSD Treatment (2011)
62. CCTA #0008 – PLIUS for the Treatment of Osteoarthritis of the Knee (2012) – funded by VA
63. Biomarker-based Randomized Clinical Trial for Treatment of Stage I Lung Cancer (2012)
64. CCTA #0009 - Central Neck Dissection in Stage 1 Thyroid Cancer (2012)
65. CSP #596 - Optimal Treatment for Recurrent Clostridium difficile Infection (2013) – funded by VA
66. CCTA #0010 - Problem Solving Prevention of Suicide Reattempt (2013)
67. CCTA #0011 - RLT100 for Treatment of Secondary Progressive Multiple Sclerosis (2013)
68. CCTA #0012 – Phase 1/2 Trial of Gene Transfer to Treat Neuropathic Pain (2013)
69. CSP #2005: Stereotactic Radiotherapy vs Surgery for Stage I Lung Cancer (2013) – funded by VA
70. CSP #598: Excellence in Peripheral Arterial Disease Treatment of Chronic Total Occlusion (2013)
71. Secondary analysis of CSP #458 (2014) – funded by VA
72. CSP 2008 – Pentoxifylline in Proteinuric Diabetic Kidney Disease (2015) – funded by VA
73. CSP #2020 - Topical versus Intracameral Moxifloxacin for Endophthalmitis (TIME) Prophylaxis Study (2019)
74. CSP #2027 - Hydroxychloroquine for Prevention of COVID-19 Infection (2020)
75. CSP #2029 – Low-dose Irradiation of Patients with Pneumonitis Secondary to SARS-CoV-2 Infection (2020)
76. Veterans Affairs phase II randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for OligoRecurrent prostate cancer (STARPORT) – (2020) funded by VA-CSR&D
77. Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain – (2020) funded by VA CSR&D)

DOCTORAL DISSERTATION COMMITTEES

1. Cambron JA: A Randomized Trial of Chiropractic Care vs. Medical Care for Low Back Pain: Assessment of Long-Term Follow-up Data (2005).
2. McFarlin BL: Assessment of Cervical Ripening (2005).

3. Monberg, M: Epogen and Head and Neck Cancer Risk (2016)
4. Bu, X: D-Optimal Designs for Multinomial Logistic Models (2017)
5. Shi H: Statistical Methods for Measuring Agreement involving Longitudinal Data (2018)

DATA AND SAFETY MONITORING BOARDS/EXTERNAL ADVISORY COMMITTEES

1. NIDDK Medical Treatment Of Prostate Symptoms Clinical Trial (1995-2002)
2. VA Ambulatory Care Quality Improvement Project Trial (1996-1999)
3. NIDDK Trial of Saw Palmetto Extract for the Treatment of Symptoms of BPH (1999-2005).
4. NIAMS Trial of Type I Collagen Treatment for Scleroderma (1999-2005).
5. NIDDK MIST Clinical Trial (2002-2007)
6. NIDDK Phase II Trial of Botulinum Toxin for Prostate Symptoms (2007 – 2012)
7. NIDDK CAMUS Clinical Trial (2009 – 2012)
8. NIAMS Phase I Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (2011-2017)
9. NIAMS Trial of Protein Therapy for Recessive Dystrophic Epidermolysis Bullosa (2011-2013)
10. Otonomy Protocol OTO – 104 (2011 – 2015)
11. DOD - Effect of AR-42 on NF2 and Non-NF2 Associated Vestibular Schwannomas and Meningiomas (2015 – present)
12. DOD - Fibroblast Growth Factor Regenerates Tympanic Membrane Perforations (2017 – 2020)
13. Member, FDA Advisory Committee, Center for Devices and Radiological Health (2015 – 2020)
14. DOD - Gulf War Illness Clinical Trials Consortium (2018 – present)
15. DOD -Tanezumab for Schwannomatosis Patients with Moderate to Severe Pain. (2018 – present)
16. Abeona Therapeutics – EB-101 (2018-present)
17. The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care (D-CARE) (2019 – Present)

REVIEW COMMITTEES

1. Ad Hoc Reviewer, AHCPR Study Section (1991)
2. Reviewer, Journal of the Society for Clinical Trials (1995-present)
3. Reviewer, Journal of Clinical Epidemiology (2001)
4. Reviewer, NIAMS review section on biomarkers for rheumatic diseases (2001)
5. Reviewer, NIDDK review section on frequent hemodialysis clinical trials (2003)
6. Reviewer, Statistics in Medicine (2004)
7. Member, VA Clinical Trials Merit Review Board (2004-2008)
8. Director, CSR&D Central Data Monitoring Committees (2010- 2020)
9. Reviewer, NIDCD Clinical Trials Review Committee (2011)
10. Reviewer, Otology & Neurotology (2011)
11. Member, VA Brain Bank Tissue Access Committee (2012 – 2016)

12. Reviewer, Audiology and Neurotology (2013 – 2015)
13. Reviewer, VA Merit Review Nephrology Panel (2017 – 2021)
14. Reviewer, NINDS StrokeNet Data Coordinating Center Review Committee (2018)
15. Reviewer, Deep Phenotyping of Gulf War Illness Merit Review Subcommittee (2018-2019)
16. Reviewer, NINDS EPPIC-NET & Stroke-Net (2019-present)
17. Reviewer, VA COVID-19 Central Biospecimen Consortium (2020)
18. Reviewer, VA Merit Review Pulmonology Panel (2020 - present)

TEACHING ACTIVITIES

1. Faculty Member, American College of Surgeons Course on Clinical Research Methods (1997-2016)
2. Faculty Member, VA Course on Clinical Research Methods (1998-2002)
3. Director, VA Course on Clinical Trials Methods (2002-2010)
4. Design and Analysis of Clinical Trials, University of Illinois at Chicago (2003-present)
5. Faculty Member, ARVO course on Principles and Concepts in Clinical Trials for Eye Researchers (2009)
6. Design and Analysis of Clinical Trials, Northwestern University (2014 – 2022)
7. Faculty Member, VA Course on Clinical Trials for PTSD Treatments (2017)
8. Analytical and Research Methods in Public Health – University of Illinois at Chicago (2021 - present)

PROFESSIONAL SOCIETY ACTIVITIES

1. Member, American Statistical Association (1976-present)
2. Member, Society for Clinical Trials (1981-present)
3. Member, Northeastern Illinois Chapter of the American Statistical Association Program Committee (1998-2007)
4. Chapter Officer, Northeastern Illinois Chapter of the American Statistical Association (2000-2001)
5. President, Northeastern Illinois Chapter of the American Statistical Association (2002)
6. Chair, Society for Clinical Trials Education Committee (2004-2009)
7. Member, Society for Clinical Trials Program Committee (2005-2014)
8. Board of Directors, Society for Clinical Trials (2005-2009)
9. Member, Strategic Planning Committee, Society for Clinical Trials (2007)
10. Member, Society for Clinical Trials Educational Outreach Committee (2009 – 2010)
11. Co-Chair, Society for Clinical Trials Education Committee (2012)
12. Co-Chair, Society for Clinical Trials Program Committee (2013)
13. Chair, Society for Clinical Trials Program Committee (2014)
14. President, Society for Clinical Trials (2016-2017)
 - Annual Meeting – Liverpool, UK, attendance - 1250
15. Secretary, Society for Clinical Trials (2018 – 2022)
16. Member, Society for Clinical Trials Equity, Diversity and Inclusion Committee (2020 – 2022)
17. Newsletter Editor, Society for Clinical Trials (2016 – 2022)
18. Executive Committee Advisor, Society for Clinical Trials (2022-present)

OTHER PROFESSIONAL ACTIVITIES:

1. Member, Hines Human Studies Subcommittee (1991-1999)
2. Member, Hines Scientist Promotion Review Panel (1993-2020)
3. Member, Design Working Group for the NIDDK Trial on BPH Treatments (1994)
4. Consultant, Veterans Information Resource Center (VIREC) (1998-2007)
5. Member, Purdue University Statistics Department Academic Advisory Council (1998-2001)
6. Invited Speaker – First International Conference on Complementary and Alternative Medicine (2001).
7. Member, Hines VA Hospital Research and Development Committee (2002-2020)
8. Invited Participant, NIAMS Osteoarthritis Biomarkers Network Steering Committee Meeting (2004)
9. Invited Participant, NIDCD Clinical Research Workshop (2005)
10. Invited Participant, VA Central IRB Focus Group (2006)
11. Steering Committee Member, Clinical Trials Transformation Initiative (2009 – 2020)
12. Chair, Cooperative Studies Program Board of Directors (2011-2013)
13. Member, Purdue University Statistics Department Academic Advisory Council (2011-2018)
14. Invited Participant, VA Point of Care Randomization Research Conference (2011)
15. Chair, VA Gulf War Research Strategic Plan Subcommittee (2011)
16. Invited Speaker, Association of VA Surgeons Annual Meeting (2016)
17. Invited Speaker, Long Beach VA Research Week (2019)
18. Invited Speaker, Society for Clinical Trials 40th Anniversary Plenary Session (2019)
19. Invited Speaker, VA Career Development Meeting (2019 – 2020))
20. Invited Speaker, VA Cooperative Studies Program Knowledge Series (2022)
21. Invited Speaker, 10th International Purdue Symposium on Statistics, June 8, 2023.
“Collaboration and Communication: Challenges for Statisticians – The Statistician as Clinical Research Development Facilitator.”

RESEARCH PUBLICATIONS:

CITATION FREQUENCY:

<u>Source</u>	<u># of Citations</u>	<u># if citations without self-citations</u>	<u>h-index</u>
<u>Scopus</u>	<u>23,448</u>	<u>22,143</u>	<u>66</u>

PUBLICATION FREQUENCY BY JOURNAL:

New England Journal of Medicine	13
JAMA	7
JAMA Internal Medicine/Archives of Internal Medicine	7
Diabetes Care	6
Hypertension	6
American Journal of Cardiology	5
Arthritis and Rheumatism	5
Journal of Urology	5
American Journal of Hypertension	4
American Journal of Medicine	4
American Journal of Surgery	4
Endocrine Research	4
Journal of the American College of Cardiology	4
Journal of the American College of Surgeons	4
Annals of Surgery	3
Journal of Diabetes and Its Complications	3
JAMA Ophthalmology/Archives of Ophthalmology	3
Journal of Rheumatology	3
Medical Care	3
Neurology	3

Alcohol	2
American Journal of Kidney Disease	2
American Journal of Nephrology	2
Cardiology Review	2
Circulation	2
Computer Methods and Programs in Biomedicine	2
Controlled Clinical Trials/Clinical Trials	2
Endocrinology	2
JAMA Dermatology/Archives of Dermatology	2
JAMA Network Open	2
JAMA Surgery/Archives of Surgery	2
Journal of Endocrinology	2
Journal of Neurology, Neurosurgery and Psychiatry	2
Life Sciences	2
Military Medicine	2
Neuroendocrinology Letters	2
Otology and Neurotology	2
Statistics in Medicine	2
Urology	2
62 other journals with 1 publication	
Total	196

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents **[Reda]**. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. results of short-term titration with emphasis on racial differences in response. JAMA, 248(16):1996-2003, (Oct 22-29) 1982.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents **[Reda]**. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. results of long-term therapy. JAMA, 248(6):2004-2011, (Oct 22-29) 1982.
3. Veterans Administration Cooperative Study Group on Antihypertensive Agents **[Reda]**. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. evaluation of the renin-angiotensin system. Am J Med, 74 (6):1029-1041, (Jun) 1983.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents **[Reda]**. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension, 7(6):1008-1016, (Nov) 1985.

5. Veterans Administration Cooperative Study Group on Antihypertensive Agents [**Reda**]. Urinary and serum electrolytes in untreated black and white hypertensives. J Chron Dis, 40(9):839-847, 1987.
6. Heringa P, Lawson L and **Reda D**. The effect of a structured education program on knowledge and psychomotor skills of patients using beclomethasone dipropionate aerosol for steroid dependent asthma. Health Educ Q, 14(3):309-317 (Fall) 1987.
7. Emanuele MA, Metcalfe L, Soneru I, **Reda D**, Kirsteins L, Emanuele NV and Lawrence AM. The effect of ethanol on prolactin release from pituitary cells in vitro. Alcohol, 4(6):429-432, (Nov – Dec) 1987.
8. Emanuele MA, Tentler J, Kirsteins L, **Reda D**, Emanuele NV and Lawrence AM. Anaesthesia with alphaxalone plus alphadolone acetate decreases serum concentrations of LH in castrated rats. J Endocrinol, 115(2):221-223, (Nov) 1987.
9. Freis E for the Veterans Administration Cooperative Study Group on Antihypertensive Agents [**Reda**]. Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril). Am J Cardiol, 61(1):117-121, (Jan) 1988.
10. Emanuele MA, Kirsteins L, **Reda D**, Emanuele NV, and Lawrence AM. The effect of in vitro ethanol exposure on basal growth hormone secretion. Endocr Res, 14(4):283-291, (Jan) 1988 - 1989.
11. Freis ED, **Reda DJ** and Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension, 12(3):244-250, (Sep) 1988.
12. Materson BJ, **Reda D**, Freis ED, Henderson WG, Veterans Administration Cooperative Study Group on Antihypertensive Agents. Cigarette smoking interferes with treatment of hypertension. Arch Int Med, 148(10):2116-2119, (Oct) 1988.
13. Emanuele MA, Tentler J, Emanuele NV, **Reda D**, Kirsteins L and Lawrence AM. In vitro effect of ethanol exposure on basal and GnRH-stimulated LH secretion from pituitary cells. Endocr Res, 15(3):393-401, 1989.
14. Waters WB, Herbster G, Jablow VR, and **Reda DJ**. Ureteral replacement using ileum in compromised renal function. J Urol, 141(2):432-436, (Feb) 1989.
15. Emanuele MA, Tentler J, **Reda D**, Kirsteins L, Emanuele NV, and Lawrence AM. In vivo effect of ethanol on release of LH - releasing hormone and LH in rats. J Endocrinol, 121(1):37-41, (Apr) 1989.
16. Emanuele MA, Tentler J, **Reda D**, Kirsteins L, Emanuele NV, and Lawrence AM. Failure of *in vitro* ethanol to inhibit LHRH release from the hypothalamus. Alcohol, 6(4):263-266, (Jul–Aug) 1989.
17. Hsu YL, **Reda DJ**. A microcomputer-based clinical trial database incorporated with an "audit trail" for correction process. Comput Methods Programs Biomed, 30(4):239-248, (Dec) 1989.
18. Emanuele MA, Tentler J, **Reda D**, Kirsteins L, Emanuele NV, and Lawrence AM. The effect of in vitro ethanol exposure on LHRH release from perfused rat hypothalami. Endocr Res, 16(3):313-321, 1990.
19. Materson BJ, Cushman WC, Goldstein G, **Reda DJ**, Freis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH, Khatri I, Schnaper H, Thomas JR, Henderson WG, Fye C for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Treatment of hypertension in the elderly. I. blood pressure and clinical changes. results of a Department of Veterans Affairs Cooperative Study. Hypertension, 15(4):348-360, (Apr) 1990.

20. Goldstein G, Materson BJ, Cushman WC, **Reda DJ**, Freis ED, Ramirez EA, Talmers FN, White TJ, Nunn S, Chapman RH, Khatri I, Schnaper H, Thomas JR, Henderson WG, Fye C for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Treatment of hypertension in the elderly, II. cognitive and behavioral function. results of a Department of Veterans Affairs Cooperative Study. Hypertension, 15(4):361-369, (Apr) 1990.
21. Azad N, Duffner L, Paloyan EB, **Reda D**, Kirsteins L, Emanuele NV and Lawrence AM. Hypothalamic prolactin stimulates the release of luteinizing hormone - releasing hormone (LHRH) from male rat hypothalamus. Endocrinology, 127(4):1928-1933, (Oct) 1990.
22. Azad N, Jurgens J, Young MR, **Reda D**, Duffner L, Kirsteins L, Emanuele NV, and Lawrence AM. Presence of luteinizing hormone - releasing hormone in rat thymus. Prog Neuroendocrine Immunology, 4:113-120, 1991.
23. Stelmack J, **Reda D**, Ahlers S, Bainbridge L, and McCray J. Reading performance of geriatric patients post exudative maculopathy. J Am Optom Assoc, 62(1):53-7, (Jan) 1991.
24. Cushman WC, Khatri I, Materson BJ, **Reda DJ**, Freis ED, Goldstein G, Ramirez EA, Talmers FN, White TJ, Nunn S, Schnaper H, Thomas JR, Henderson WG and Fye C, Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Treatment of hypertension in the elderly. III. response of isolated systolic hypertension to various doses of hydrochlorothiazide. results of a Department of Veterans Affairs Cooperative Study. Arch Int Med, 151(10):1954-1960, (Oct) 1991.
25. Emanuele NV, Tentler J, Metcalfe L, Scanlon S, **Reda D**, Kirsteins L and Lawrence AM. Intracerebroventricular luteinizing hormone (LH) depresses feeding in male rats. Neuro Endocrinol Lett, 13(6):413-418, (Dec) 1991.
26. Young MJ **Reda DJ** and Waters WB. Penile carcinoma: a twenty-five-year experience. Urology, 38(6):529-532, (Dec) 1991.
27. Azad N, Kirsteins L, Nayyar R, Cernius M, **Reda D**, Emanuele NV, and Lawrence AM. The effect of diethylstilbestrol (DES) on hypothalamic prolactin-like immunoreactive protein in hypophysectomized female rats. Neuro Endocrinol Lett, 14(3):133-140, (Jun) 1992.
28. Materson BJ, **Reda DJ**, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, and Henderson WG for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med, 328(13):914-921, (Apr 1) 1993.
29. Sandouk T, **Reda D** and Hofmann C. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol, 264(6):C1600-C1608, (Jun) 1993.
30. Sandouk T, **Reda D** and Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology, 133(1):352-359, (Jul) 1993.
31. The Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia [**Reda**]. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol, 150(5):1696-1700, (Nov) 1993.

32. Uddin S, Emanuele MA, Emanuele NV, **Reda D**, Kelley MR. The effect of in vitro ethanol exposure on luteinizing hormone and follicle stimulating hormone mRNA levels, content, and secretion. Endocr Res, 20(2):201-217, 1994.
33. Jonler M, Wasson JH, **Reda DJ** and Bruskevitz RC "Analysis of Watchful Waiting Studies," in Benign Prostatic Hyperplasia: Recent Progress in Clinical Research and Practice, Kurth, K.H. and Newling, D.W. (Eds.), Wiley-Liss, Inc., New York, pp. 291-302, 1994.
34. Materson BJ and **Reda DJ**. Correction: single-drug therapy for hypertension in men. N Engl J Med, 330:1689, (Jun 9) 1994.
35. Gottdiener JS, **Reda DJ**, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, Williams DW, Henderson WG for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Importance of obesity, race, and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol, 24(6):1492-1498, (Nov 15) 1994.
36. Wasson JH, **Reda DJ**, Bruskevitz RC, Elinson J, Keller AM and Henderson WG for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med, 332(2):75-79, (Jan 12) 1995.
37. Materson BJ, **Reda DJ**, and Cushman WC for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hyperten, 8(2):189-192, (Feb) 1995.
38. Reiber GE, McDonell MB, Schleyer AM, Fihn SD, **Reda DJ**. A comprehensive system for quality improvement in ambulatory care: assessing the quality of diabetes care. Patient Educ Couns 26(1-3):337-341, (Sep) 1995.
39. Materson BJ, **Reda DJ**, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Int Med, 155(16):1757-1762, (Sep 11) 1995.
40. Materson BJ, **Reda DJ**, Cushman WC and Henderson WG for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens, 9(10):791-796, (Oct) 1995.
41. Kokkinos PF, Narayan P, Colleran JA, Pittaras A, Notargiacomo A, **Reda D** and Papademetriou V. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med, 333(22):1462-1467, (Nov 30) 1995.
42. Lakshman MR, **Reda D**, Materson BJ, Cushman WC, Kochar MS, Nunn S, Hamburger RJ and Freis ED for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Comparison of plasma lipid and lipoprotein profiles in hypertensive black versus white men. Am J Cardiol, 78(11):1236-1241, (Dec 1) 1996.
43. Materson BJ, **Reda DJ** and Williams D for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Lessons from combination therapy in Veterans Affairs studies. Am J Hypertens, 9(12):187S-191S, (Dec) 1996.

44. Clegg DO, **Reda DJ**, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher Jr HR, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Ward RH, Manaster BJ, Anderson RJ, Ward JR and Henderson WG. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 39(12):2004-2012, (Dec) 1996.
45. Clegg DO, **Reda DJ**, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher Jr HR, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Ward RH, Manaster BJ, Anderson RJ, Ward JR and Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 39(12):2013-2020, (Dec) 1996.
46. Clegg DO, **Reda DJ**, Weisman MH, Cush JJ, Vasey FB, Schumacher Jr HR, Budiman-Mak E, Balestra DJ, Blackburn WD, Cannon GW, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald ML, Higashida J, Silverman SL, Parhammi N, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR and Henderson WG. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's Syndrome): a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 39(12):2021-2027, (Dec) 1996.
47. Lakshman MR, **Reda DJ**, Materson BJ and Cushman WC for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Lipoprotein profiles of hypertensive black and white men: does race influence risk? Cardiol Rev, 14:10:51-57, 1997.
48. Gottdiener JS, **Reda DJ**, Williams DW, Materson BJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Left atrial size in hypertensive men: influence of obesity, race and age. J Am Coll Cardiol, 29(3):651-658, (Mar 1) 1997.
49. Bruskwitz RC, **Reda DJ**, Wasson JH, Barrett L and Phelan M. Testing to predict outcome after transurethral resection of the prostate. J Urol, 157(4):1304-1308, (Apr) 1997.
50. Gottdiener JS, **Reda DJ**, Massie BM, Materson BJ, Williams DW and Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation, 95(8):2007-2014, (Apr 15) 1997.
51. Preston RA, Materson BJ, **Reda DJ**, Hamburger RJ, Williams DW, Smith MH for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Clin Nephrol, 47(5):310-315, (May) 1997.
52. Sadler DB, Aurigemma GP, Williams DW, **Reda DJ**, Materson BJ, and Gottdiener JS. Systolic function in hypertensive men with concentric remodeling. Hypertension, 30(4):777-781, (Oct) 1997.
53. Materson BJ, **Reda DJ** and Williams DW for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Comparison of effects of antihypertensive drugs on heart rate: changes from baseline by baseline group and over time. Am J Hypertens, 11(5):597-601, (May) 1998.

54. Flanigan RC, **Reda DJ**, Wasson JH, Anderson RJ, Abdellatif M and Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative Study. J Urol, 160(1):12-17, (Jul) 1998.
55. Gottdiener JS, **Reda DJ**, Williams DW, Materson BJ, Cushman W and Anderson RJ for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: Comparison of six antihypertensive agents. Circulation, 98(2):140-148, (Jul 14) 1998.
56. Kaufman JS, **Reda DJ**, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, and Vaamonde CA for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med, 339(9):578-583, (Aug 27) 1998.
57. Preston RA, Materson BJ, **Reda DJ**, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA, 280(13):1168-1172, (Oct 7) 1998.
58. Kaufman JS for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. [**Reda**]. Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis, 32(6):S147-S151, (Dec) 1998.
59. Battistone MJ, Manaster BJ, **Reda DJ** and Clegg DO. Radiographic diagnosis of sacroiliitis- are sacroiliac views really better? J Rheumatol, 25(12):2395-2401, (Dec) 1998.
60. Materson BJ, **Reda DJ**, and Williams DW for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effects of antihypertensive single-drug therapy on heart rate. Am J Hypertens, 12(1):9S-11S, (Jan) 1999.
61. Lakshman MR, **Reda DJ**, Materson BJ, Cushman WC, Freis ED for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Diuretics and β -blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Int Med, 159(6):551-558, (Mar 22) 1999.
62. Hynes D, **Reda D**, Giobbie-Hurder A, Abdellatif M, Weinberger M, Oddone E, Wasson J and Henderson W. Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. Med Care, 37(4):AS27-AS36, (Apr) 1999.
63. Battistone MJ, Manaster BJ, **Reda DJ** and Clegg DO. The prevalence of sacroiliitis in psoriatic arthritis: new perspectives from a large, multicenter cohort: A Department of Veterans Affairs Cooperative Study. Skeletal Radiol, 28(4):196-201, (Apr) 1999.
64. Abdellatif M, **Reda DJ**, Williams D, Cushman WC and Materson BJ. Accessing data from external centralized sources to enhance analysis of a completed clinical trial. J Med Syst, 23(3):183-188, (Jun) 1999.
65. Cohen MR, **Reda DJ** and Clegg DO for the Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. Baseline relationships between psoriasis and psoriatic arthritis: an analysis of 221 patients with active psoriatic arthritis. J Rheumatol, 26(8):1752-1756, (Aug) 1999.

66. Weinblatt ME, **Reda D**, Henderson W, Giobbie-Hurder A, Williams D, Diani A and Docsa S. Sulfasalazine treatment for rheumatoid arthritis. a meta-analysis of 15 randomized trials. J Rheumatol, 26(10):2123-2130, (Oct) 1999.
67. Clegg DO, **Reda DJ**, and Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum, 42(11):2325-2329, (Nov) 1999.
68. Lakshman MR, **Reda DJ**, Materson BJ, Cushman WC and Freis ED for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Are the lipid effects of antihypertensive agents serious? Cardiol Rev, 17:38-42, (Jan) 2000.
69. Cushman WC, **Reda DJ**, Perry Jr. HM, Williams D, Abdellatif M and Materson BJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Int Med, 160(6):825-831, (Mar 27) 2000.
70. Preston RA, Materson BJ, **Reda DJ**, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Int Med, 160(10):1449-1454, (May 22) 2000.
71. Aurigemma GP, Williams D, Gaasch WH, **Reda DJ**, Materson BJ and Gottdiener JS. Ventricular and myocardial function following treatment of hypertension. Am J Cardiol, 87(6):732-736, (Mar 15) 2001.
72. Kaufman JS, **Reda DJ**, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG and Vaamonde CA for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int, 60(1):300-308, (Jul) 2001.
73. Cushman WC, Materson BJ, Williams DW, **Reda DJ** for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension, 38(4):953-957, (Oct) 2001.
74. Hynes DM, Stroupe KT, Greer JW, **Reda DJ**, Frankenfield DL, Kaufman JS, Henderson WG, Owen Jr WF, Rocco MV, Wish JB, Kang J, Feussner JR. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med, 112(3):169-175, (Feb 15) 2002.
75. Collins EG, Langbein WE, Orebaugh C, Bammert C, Hanson K, **Reda D**, Edwards LC, and Littooy FN. PoleStriding exercise and vitamin E for management of peripheral vascular disease. Med Sci Sports Exerc, 35(3):384-393, (Mar) 2003.
76. Materson BJ, Williams DW, **Reda DJ**, Cushman WC for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial. J Clin Hypertens, 5:197-201, (May-Jun) 2003.
77. Fitzgibbons Jr RJ, Jonasson O, Gibbs J, Dunlop DD, Henderson W, **Reda D**, Giobbie-Hurder A, McCarthy Jr M. The development of a clinical trial to determine if watchful waiting is an acceptable alternative to routine herniorrhaphy for patients with minimal or no hernia symptoms. J Am Coll Surg, 196(5):737-742, (May) 2003.

78. Neumayer L, Jonasson O, Fitzgibbons Jr. R, Henderson W, Gibbs J, Carrico CJ, Itani K, Kim L, Pappas T, **Reda D**, Dunlop D, McCarthy M, Hynes D, Giobbie-Hurder A, London MJ, Hatton-Ward S. Tension-free inguinal hernia repair: the design of a trial to compare open and laparoscopic surgical techniques. J Am Coll Surg, 196(5):743-752, (May) 2003.
79. Singh SN, Singh BN, **Reda DJ**, Fye CL, Ezekowitz, MD, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis Jr. HD, Antman EM, Falk RH, Lopez B and Tang XC. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation – (Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol, 92(4):468-472, (Aug 15) 2003.
80. Abaira C, Duckworth W, McCarren M, Emanuele N, Arca D, **Reda D**, Henderson W for the participants of the VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs Diabetes Trial. J Diabetes Complicat, 17(6):314-322, (Nov-Dec) 2003.
81. Abdellatif M and **Reda DJ**. A Paradox-based data collection and management system for multi-center randomized clinical trials. Comput Methods Programs Biomed, 73(2):145-164, (Feb) 2004.
82. Neumayer L, Giobbie-Hurder A, Jonasson O, Fitzgibbons Jr. R, Dunlop D, Gibbs J, **Reda D**, and Henderson W for the Veterans Affairs Cooperative Studies Program 456 Investigators. Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med, 350(18):1819-1827, (Apr 29) 2004.
83. Collins E, Langbein WE, Dilan-Koetje J, Bammert C, Hanson K, **Reda D** and Edwards L. Effects of exercise training on aerobic capacity and quality of life in individuals with heart failure. Heart Lung, 33(3):154-161, (May-Jun) 2004.
84. Oddone EZ, Olsen MK, Hoff Lindquist J, Orr M, Horner R, **Reda D**, Lavori P, Johnson G, Collins J, Feussner JR. Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000). Cont Clin Trials, 25(4):378-387, (Aug) 2004.
85. Davis LE, Eisen SA, Murphy FM, Alpern R, Parks BJ, Blanchard M, **Reda DJ**, King MK, Mithen FA and Kang, HK. Clinical and laboratory assessment of distal peripheral nerves in Gulf War veterans and spouses. Neurology, 63(6):1070-1077, (Sep 28) 2004.
86. Itani KMF, Neumayer L, **Reda D**, Kim L, Anthony T. Repair of ventral incisional hernia: the design of a randomized trial to compare open and laparoscopic surgical techniques. Am J Surg, 188(6A):22S-29S, (Dec) 2004.
87. Karlinsky JB, Blanchard M, Alpern R, Eisen SA, Kang H, Murphy FM, **Reda DJ**. Late prevalence of respiratory symptoms and pulmonary function abnormalities in Gulf War IVeterans. Arch Int Med, 164(22):2488-2491, (Dec 13) 2004.
88. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, **Reda DJ**, and Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med, 351(27):2795-2804, (Dec 30) 2004.
89. Stroupe KT, Hynes DM, Giobbie-Hurder A, Oddone EZ, Weinberger M, **Reda DJ**, and Henderson WG. Patient satisfaction and use of Veterans Affairs versus non-Veterans Affairs healthcare services by veterans. Med Care, 43(5):453-460, (May) 2005.

90. Collins EG, Langbein WE, Orebaugh C, Bammert C, Hanson K, **Reda D**, Edwards LC, Littooy FN. Cardiovascular training effect associated with polestriding exercise in patients with peripheral arterial disease. J Cardiovasc Nurs, 20(3):177-185, (May-Jun) 2005.
91. Singh BN, Singh, SN, **Reda DJ**, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis Jr HD, Raisch DW, Ezekowitz MD for the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med, 352(18):1861-1872, (May 5) 2005.
92. Eisen SA, Kang HK, Murphy FM, Blanchard MS, **Reda DJ**, Henderson WG, Toomey R, Jackson LW, Alpern R, Parks BJ, Klimas N, Hall C, Pak HS, Hunter J, Karlinsky J, Battistone MJ, Lyons MJ and the Gulf War Study Participating Investigators. Gulf War veterans' health: medical evaluation of a U. S. cohort. Ann Int Med, 142(11):881-890, (Jun 7) 2005.
93. Emanuele N, Sacks J, Klein R, **Reda D**, Anderson R, Duckworth W, Abaira C, for the Veterans Affairs Diabetes Trial Group. Ethnicity, race and baseline retinopathy correlates in the Veterans Affairs Diabetes Trial. Diabetes Care, 28(8):1954-1958, (Aug) 2005.
94. Neumayer LA, Gawande AA, Wang J, Giobbie-Hurder A, Itani KMF, Fitzgibbons Jr RJ, **Reda D**, Jonasson O and the CSP #456 Investigators. Proficiency of surgeons in inguinal hernia repair effect of experience and age. Ann Surg, 242(3):344-348, (Sep) 2005
95. Blanchard MS, Eisen SA, Alpern R, Karlinsky J, Toomey R, **Reda DJ**, Murphy FM, Jackson LW and Kang HK. Chronic multisymptom illness complex in Gulf War I veterans 10 years later. Am J Epi, 163(1):66-75, (Jan 1) 2006.
96. Barnhill JG, Fye CL, Williams DW, **Reda DJ**, Harris CL and Clegg DO. Chondroitin product selection for the Glucosamine/Chondroitin Arthritis Intervention Trial. J Am Pharm Assoc, 46(1):14-24, (Jan-Feb) 2006.
97. Fitzgibbons Jr RJ, Giobbie-Hurder A, Gibbs JO, Dunlop DD, **Reda DJ**, McCarthy Jr M, Neumayer LA, Barkun JST, Hoehn JL, Murphy JT, Sarosi Jr. GA, Syme WC, Thompson JS, Wang J and Jonasson O. Watchful waiting vs repair of inguinal hernia in minimally symptomatic men. JAMA, 295(3):285-292, (Jan 18) 2006.
98. Clegg, DO, **Reda DJ**, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham III CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher Jr HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW and Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med, 354(8):795-808, (Feb 23) 2006.
99. Hynes DM, Stroupe KT, Kaufman JS, **Reda DJ**, Peterman A, Browning MM, Huo Z, and Sorbara D for the ESRD Cost Study Group. Adherence to guidelines for ESRD anemia management. Am J Kidney Dis, 47(3):455-461, (Mar) 2006.
100. Eisen SA, Karlinsky J, Jackson LW, Blanchard M, Kang HK, Murphy FM, Alpern R, **Reda DJ**, Toomey R, Battistone MJ, Parks BJ, Klimas N, Pak HS, Hunter J, Lyons MJ, Henderson WG, Gulf War Study Participating Investigators. Spouses of Persian Gulf War I veterans: medical evaluation of a U.S. cohort. Mil Med, 171(7):613-618, (Jul) 2006.
101. Singh SN, Tang XC, Singh, BN, Dorian P, **Reda DJ**, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis Jr. HD, Lopez B, Raisch DW, Ezekowitz MD for the SAFE-T Investigators. Quality of life and exercise performance in patients in sinus

- rhythm versus persistent atrial fibrillation. a Veterans Affairs Cooperative Studies Program substudy. *J Am Coll Cardiol*, 48(4):721-730, (Aug 15) 2006.
102. Ward HB, Kelly RF, Thottapurathu L, Moritz TE, Larsen GC, Pierpont G, Santilli S, Goldman S, Krupski WC, Littooy F, **Reda DJ**, and McFalls EO. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. *Ann Thorac Surg*, 82(3):795-801, (Sep) 2006.
 103. Hynes DM, Stroupe KT, Luo P, Giobbie-Hurder A, **Reda D**, Kraft M, Itani K, Fitzgibbons R, Jonasson O, Neumayer L for the Veterans Affairs Cooperative Studies Program 456 Investigators. Cost effectiveness of laparoscopic versus open mesh hernia operation: results of a Department of Veterans Affairs randomized clinical trial. *J Am Coll Surg*, 203(4):447-457, (Oct) 2006.
 104. Stroupe KT, Manheim LM, Luo P, Giobbie-Hurder A, Hynes DM, Jonasson O, **Reda DJ**, Gibbs JO, Dunlop DD, Fitzgibbons Jr RJ. Tension-free repair versus watchful waiting for men with asymptomatic or minimally symptomatic inguinal hernias: a cost-effectiveness analysis. *J Am Coll Surg*, 203(4):458-468, (Oct) 2006.
 105. Stelmack JA, Tang XC, **Reda DJ**, Moran D, Rinne S, Mancil RM, Cummings R, Mancil G, Stroupe K, Ellis N and Massof RW. The Veterans' Affairs Low Vision Intervention Trial (LOVIT): design and methodology. *Clin Trials*, 4(6):650-660, 2007.
 106. Atwood JE, Myers JN, Tang XC, **Reda DJ**, Singh SN, Singh BN. Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). *Am Heart J*, 153(4):566-572, (Apr) 2007.
 107. Toomey R, Kang HK, Karlinsky J, Baker DG, Vasterling JJ, Alpern R, **Reda DJ**, Henderson WG, Murphy FM and Eisen SA. Mental health of US Gulf War veterans 10 years after the war. *Brit J Psychiatry*, 190(5):385-393, (May) 2007.
 108. Batcher EL, Tang XC, Singh BN, Singh SN, **Reda DJ**, Hershman JM for the SAFE-T Investigators. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. *Am J Med*, 120(10):880-885, (Oct) 2007.
 109. McFalls EO, Ward HB, Moritz TE, Littooy F, Santilli S, Rapp J, Larsen G, and **Reda DJ**. Clinical factors associated with long-term mortality following vascular surgery: outcomes from The Coronary Artery Revascularization Prophylaxis (CARP) Trial. *J Vasc Surg*, 46(4):694-700, (Oct) 2007.
 110. Matthews RD, Anthony T, Kim LT, Wang J, Fitzgibbons Jr. RJ, Giobbie-Hurder A, **Reda DJ**, Itani KMF, Neumayer LA for the Veterans Affairs Cooperative 456 Studies Program Investigators. Factors associated with postoperative complications and hernia recurrence for patients undergoing inguinal hernia repair: a report from the VA Cooperative Hernia Study Group. *Am J Surg*, 194(5):611-617, (Nov) 2007.
 111. Thomson JS, Gibbs JO, **Reda DJ**, McCarthy Jr M, Wei Y, Giobbie-Hurder A and Fitzgibbons Jr RJ. Does delaying repair of an asymptomatic hernia have a penalty? *Am J Surg*, 195(1):89-93, (Jan) 2008.
 112. McFalls EO, Ward HB, Moritz TE, Apple FS, Goldman S, Pierpont G, Larsen GC, Hattler B, Shunk K, Littooy F, Santilli S, Rapp J, Thottapurathu L, Krupski W, **Reda DJ**, and Henderson WG. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP Trial. *Eur Heart J*, 29(3):394-401, (Feb) 2008.

113. Stroupe KT, Stelmack JA, Tang XC, **Reda DJ**, Moran D, Rinne S, Mancil R, Wei Y, Cummings R, Mancil G, Ellis N, and Massof RW. Economic evaluation of blind rehabilitation for veterans with macular diseases in the Department of Veterans Affairs. Ophthalmic Epidemiol, 15(2):84-91, (Mar-Apr) 2008.
114. Collins EG, Langbein WE, Fehr L, O'Connell S, Jelinek C, Hagarty E, Edwards L, **Reda D**, Tobin MJ, and Laghi F. Can ventilation-feedback training augment exercise tolerance in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med, 177(8):844-852, (Dec 1) 2008.
115. Stelmack JA, Tang XC, **Reda DJ**, Rinne S, Mancil RL, Massof RW for the LOVIT Study Group. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol, 126(5):608-617, (May) 2008.
116. Garcia S, Moritz TE, Ward HB, Pierpont G, Goldman S, Larsen GC, Littooy F, Krupski W, Thottapurathu L, **Reda DJ**, and McFalls EO. Usefulness of revascularization of patients with multivessel coronary artery disease before elective vascular surgery for abdominal aortic and peripheral occlusive disease. Am J Cardiol, 102(7):809-813, (Oct 1) 2008
117. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham III CO, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, **Reda DJ**, Moskowitz RW, Williams HJ and Clegg DO. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum, 58(10):3183-3191, (Oct) 2008.
118. Garcia S, McFalls EO, Goldman S, Larsen GC, Littooy F, Moritz TE, **Reda DJ**, Ward HB, Shunk K and Hattler B. Diagnostic coronary angiography in patients with peripheral arterial disease: a sub-study of the Coronary Artery Revascularization Prophylaxis Trial. J Interv Cardiol, 21(5):369-374, (Oct) 2008
119. Saban KL, Stroupe KT, Bryant FB, **Reda DJ**, Browning MM, and Hynes DM. Comparison of health-related quality of life measures for chronic renal failure: quality of well-being scale, short-form-6d and the kidney disease quality of life instrument. Qual Life Res, 17(8):1103-1115, (Oct) 2008.
120. Patel T, Hirter A, Kaufman J, Keithi-Reddy SR, **Reda D**, and Singh A. Route of epoetin administration influences hemoglobin variability in hemodialysis patients. Am J Nephrol, 29(6):532-537, (Jun) 2009.
121. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks Jr WJ, Rothlind J, Sagher O, **Reda D**, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J and Huang GD for the CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA, 301(1):63-73, (Jan 7) 2009.
122. Duckworth W, Abaira C, Moritz T, **Reda D**, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, and Huang GD for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 360(2):129-139, (Jan 8) 2009.

123. Singh SN, Tang XC, **Reda D**, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm, 6(2):152-155, (Feb) 2009.
124. Rauch SD, **Reda DJ**, Collaborating Investigators, Sudden SNHL Multicenter Treatment Trial. Combined therapy (intratympanic dexamethasone + high-dose prednisone taper) for idiopathic sudden sensorineural hearing loss. Otol Neurotol, 30:254-256, 2009.
125. Garcia S, Moritz TE, Goldman S, Littooy F, Pierpont G, Larsen GC, **Reda DJ**, Ward HB, and McFalls EO. Perioperative complications after vascular surgery are predicted by the revised cardiac risk index but are not reduced in high-risk subsets with preoperative revascularization. Circ Cardiovasc Qual Outcomes, 2(2):73-77, (Mar) 2009.
126. Barnhill JG, Fye CL, **Reda DJ**, Harris CL and Clegg DO. Is all glucosamine alike? Clarifying the controversies for product selection and clinical research. J Complement Integr Med: Vol. 6(1): Article 17, (Jun 23) 2009.
127. Emanuele N, Klein R, Moritz T, Davis MD, Glander K, Anderson R, **Reda D**, Duckworth W, Abaira C for the VADT Study Group. Comparison of dilated fundus examinations with seven-field stereo fundus photographs in the Veterans Affairs Diabetes Trial (VADT). J Diabetes Complicat, 23(5):323-329, (Sep-Oct) 2009.
128. Toomey R, Alpern R, Vasterling JJ, Baker DG, **Reda DJ**, Lyons MJ, Henderson WG, Kang HK, Eisen SA and Murphy FM. Neuropsychological functioning of U.S. Gulf War veterans 10 years after the war. J Int Neuropsych Soc, 15:717-729, (Sep) 2009.
129. Kaafarani HMA, Hur K, Hirter A, Kim LT, Thomas A, Berger DH, **Reda D**, and Itani KMF. Seroma in ventral incisional herniorrhaphy: incidence, predictors and outcome. Am J Surg, 198(5):639-644, (Nov) 2009.
130. Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, Emanuele N, Kayshap M, Marks J, Mudaliar S, Rao RH, Shah JH, Goldman S, **Reda DJ**, McCarren M, Abaira C, Duckworth W, for the Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in Veterans Affairs Diabetes Trial participants with lower calcified coronary atherosclerosis. Diabetes, 58(11):2642-2648, (Nov) 2009.
131. Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, **Reda D**, Warren S, and Garewal H. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol, 182(5):2257-2264, (Nov) 2009.
132. Itani KMF, Hur K, Kim LT, Thomas A, Berger DH, **Reda D** and Neumayer L for the Veterans Affairs Ventral Incisional Hernia Investigators. Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia a randomized trial. Arch Surg, 145(4):322-328, (Apr) 2010.
133. Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, VanVeldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, and **Reda DJ**. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology, 75(5):1138-1143, (May) 2010.
134. Kaafarani HMA, Hur K, Campasano M, **Reda DJ**, and Itani KMF. Classification and valuation of postoperative complications in a randomized trial of open versus laparoscopic ventral herniorrhaphy. Hernia, 14(3):231-235, (Jun) 2010.
135. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks, Jr. WJ, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K,

- Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R., Baltuch G, De Salles A, Huang GD, **Reda DJ** for the CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's Disease. *N Engl J Med*, 362(22):2077-91, (Jun 3) 2010.
136. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Bingham CO, **Reda DJ**, Moskowitz RW, Williams HJ, Clegg DO. Clinical efficacy and safety of glucosamine, chondroitin sulfate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. *Ann Rheum Dis*, 69(8):1459-1464, (Aug) 2010.
 137. Kaafarani HMA, Kaufman D, **Reda D**, Itani KMF. Predictors of surgical site infection in laparoscopic and open ventral incisional herniorrhaphy. *J Surg Res*, 163(2):229-234, (Oct) 2010.
 138. Saban KL, Bryant FB, **Reda DJ**, Stroupe KT and Hynes DM. Measurement invariance of the kidney disease and quality of life instrument (KDQOL-SF) across veterans and non-veterans. *Health Qual. Life Outcomes*, 8:120, (Oct 25) 2010.
 139. Garcia S, Rider JE, Moritz TE, Pierpont G, Goldman S, Larsen GC, Shunk K, Littooy F, Santilli S, Rapp J, **Reda DJ**, Ward HB and McFalls EO. Preoperative coronary artery revascularization and long-term outcomes following abdominal aortic vascular surgery in patients with abnormal myocardial perfusion scans: a subgroup analysis of the Coronary Artery Revascularization Prophylaxis Trial. *Catheter Cardiovasc Interv*, 77(1):134-141, (Jan 1) 2011.
 140. Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, Bakaeen FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, **Reda D**, Harrison L, Wagner TH, Wang Y, Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih M-C, and Lee K. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. *JAMA*, 305(2):167-174, (Jan 12) 2011.
 141. Sarosi GA, Wei Y, Gibbs JO, **Reda DJ**, McCarthy M, Fitzgibbons RJ, Barkun JST. A clinician's guide to patient selection for watchful waiting management of inguinal hernia. *Ann Surg*, 253(3):605-610, (Mar) 2011.
 142. Rauch SD, Halpin CF, Antonelli, PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes LS, Shi H, Slattery WH, Telian SA, Vrabc JT, **Reda DJ**. Oral vs. intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. *JAMA*, 305(20):2071-2079, (May 25) 2011.
 143. Duckworth WC, Abaira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, **Reda DJ**, Warren SR, Zieve FJ, for the Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. *J Diabetes Complicat*, 25(6):355-361, (Nov-Dec) 2011.
 144. Collins EG, McBurney C, Butler J, Jelinek C, O'Connell S, Fritschi C and **Reda D**. The effects of walking or walking-with-poles training on tissue oxygenation in patients with peripheral arterial disease. *Int J Vasc Med*, Article ID 985025, (Sep) 2012.

145. Hynes DM, Stroupe KT, Fischer MJ, **Reda, DJ**, Manning W, Browning MM, Huo Z, Saban K, and Kaufman JS for ESRD Cost Study Group. Comparing VA and private sector healthcare costs for end-stage renal disease. Med Care, 50(2):161-170, (Feb) 2012.
146. Collins EG, O'Connell S, McBurney C, Jelinek C, Butler J, **Reda D**, Gerber BS, Hurt C, Grabiner M. Comparison of walking with poles and traditional walking for peripheral arterial disease rehabilitation. J Cardiopulm Rehabil Prev, 32(4):210-8, (Jul-Aug) 2012.
147. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks Jr. WJ, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, **Reda DJ**, for the CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology, 79(1):55-65, (Jul) 2012.
148. Halpin, C. Shi H, **Reda D**, Antonelli PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes LS, Slattery WH, Telian SA, Vrabec JT, and Rauch S. Audiology in the sudden hearing loss clinical trial. Otol Neurotol, 33(6):907-11, (Aug) 2012.
149. Stelmack JA, Tang XC, Wei Y, Massof RW for the Low-Vision Intervention Trial Study Group (**Reda**). The effectiveness of low-vision rehabilitation in 2 cohorts derived from the Veterans Affairs Low-Vision Intervention Trial. Arch Ophthalmol, 130(9):1162-1168, (Sep) 2012.
150. Stelmack JA, Tang XC, **Reda DJ**; Stroupe KT, Rinne S, Massof RW for the LOVIT II Study Group. VA LOVIT II: a protocol to compare low vision rehabilitation and basic low vision. Ophthalmic Physiol Opt, 32(6):461-471, (Nov) 2012.
151. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King III S, Colling C, Moritz T, Stroupe K, and **Reda D** for the VA CARDS Investigators. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol, 61(8):808-816, (Feb 26) 2013.
152. Whited JD, Warshaw EM, Edison KE, Kapur K, Thottapurathu L, Raju S, Cook B, Engasser H, Pullen S, Parks P, Sindowski T, Motyka D, Brown R, Moritz TE, Datta SK, Chren M-M, Marty L, and **Reda DJ**. Effect of store and forward teledermatology on quality of life a randomized controlled trial. JAMA Dermatol, 149(5):584-591, (May) 2013.
153. Whited JD, Warshaw EM, Kapur K, Edison KE, Thottapurathu L, Raju S, Cook B, Engasser H, Pullen S, Moritz TE, Datta SK, Marty L, Foman NA, Suwattee P, Ward DS and **Reda DJ**. Clinical course outcomes for store and forward teledermatology versus conventional consult processes: a randomized trial. J Telemed Telecare, 19(4):197-204, (Jun) 2013.
154. Bhaumik DK, Kapur K, Bhaumik R, and **Reda DJ**. Sample size determination and hypothesis testing for the mean of a lognormal distribution. J Environ Stat, 5(1):1-21, (Aug) 2013.
155. Fitzgibbons Jr. RJ, Ramanan B, Arya S, Turner SA, Li X, Gibbs JO and **Reda DJ**. Investigators of the Original Trial. Long-term results of a randomized clinical trial of nonoperative strategy (watchful waiting) for men with minimally symptomatic inguinal hernias. Ann Surg, 258(3):508-515, (Sep) 2013.
156. Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, Follett KA, **Reda D**, and

- Weaver FM for the CSP 468 Study Group. Suicide ideation and behaviors after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 84(10):1113-1118, (Oct) 2013.
157. Collins EG, Jelinek C, O'Connell S, Butler J, McBurney C, Gozali C, **Reda D**, and Laghi F. Contrasting breathing retraining and helium-oxygen during pulmonary rehabilitation in COPD: a randomized clinical trial. Respir Med, 108(2):297-306, (Feb) 2014.
 158. Banerjee S, Abu Fadel M, Sarode R, Terada L, Moritz T, Luo P, Hastings J, Brilakis ES, and **Reda D**. Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. J Clin Apher, 29(2):97-106, (Apr) 2014.
 159. Bakaeen FG, **Reda DJ**, Gelijns AC, Cornwell L, Omer S, Al Jurdi R, Koungias P, Anaya D, Berger DH, and Huang GD. Department of Veterans Affairs Cooperative Studies Program Network of Dedicated Enrollment Sites implications for surgical trials. JAMA Surg, 149(6):507-513, (Jun) 2014
 160. Kapur K, Bhaumik R, Tang XC, Hur K, **Reda DJ**, and Bhaumik DK. Sample size determination for longitudinal designs with binary response. Statist Med, 33(22):3781-3800, (Sep 28) 2014.
 161. Katz M, San Luciano M, Carlson K, Luo P, Marks Jr. WJ, Larson PS, Starr PA, Follett KA, Weaver FM, Stern MB, **Reda DJ**, Ostrem JL and CSP 468 study group. Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease. Ann Neurol, 77(4):710-719, (Apr) 2015.
 162. Rothlind JC, York MK, Carlson K, Luo P, Marks Jr WJ, Weaver FM, Stern M, Follett K, **Reda D** for the CSP-468 Study Group. Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy. J Neurol Neurosurg Psychiatry, 86(6):622-629, (Jun) 2015.
 163. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, **Reda DJ**, Ge L, McCarren M, Duckworth WC and Emanuele NV for the VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 372(23):2197-2206, (Jun 4) 2015.
 164. Pape T L-B, Rosenow JM, Steiner M, Parrish T, Guernon A, Harton B, Patil V, Bhaumik DK, McNamee S, Walker M, Froehlich K, Burrell C, Odle C, Wang X, Herrold AA, Zhao W, **Reda D**, Mallinson T, Conneely M, Nemeth AJ. Placebo-controlled trial of familiar auditory sensory training for acute severe traumatic brain injury: a preliminary report. Neurorehabil Neural Repair, 29(6):537-547, (Jun) 2015.
 165. Florez H, Reaven PD, Bahn G, Moritz T, Warren S, Marks J, **Reda D**, Duckworth W, Abaira C, Hayward R, and Emanuele N from the VADT Research Group. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetes Obes Metab, 17(10):949-955, (Oct) 2015.
 166. Datta SK, Warshaw EM, Edison KE, Kapur K, Thottapurathu L, Moritz TE, **Reda DJ**, Whited JD. Cost and utility analysis of a store-and-forward teledermatology referral system a randomized clinical trial. JAMA Dermatol, 151(12):1323-1329, (Dec) 2015.
 167. Leehey DJ, Collins E, Kramer HJ, Cooper C, Butler J, McBurney C, Jelinek C, **Reda D**, Edwards L, Garabedian A, O'Connell S. Structured exercise in obese diabetic patients with chronic kidney disease: a randomized controlled trial. Am J Nephrol, 44(1):54-62, (Jul) 2016.
 168. Azad N, Bahn GD, Emanuele NV, Agrawal L, Ge L, **Reda D**, Klein R, Reaven PD,

- Hayward R and the VADT Study Group. Association of blood glucose control and lipids with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care, 39(5):816-822, (May) 2016.
169. Blanchard M, Toomey R, Karlinsky J, **Reda D**, Alpern R, Li X. Increased risk of chronic multisymptom illness in spouses of Gulf War Era veterans. Mil Med, 182(5/6): e1648-e1656, (May/June) 2017.
 170. Hartnick C, Ballif C, De Guzman V, Sataloff R, Campisi P, Kerschner J, Shembel A, **Reda D**, Shi H, Sheryka Zacny E, Bunting G. Indirect vs direct voice therapy for children with vocal nodules a randomized clinical trial. JAMA Otolaryngol Head Neck Surg, 144(2):1-8. (Jan) 2018.
 171. Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, **Reda DJ**, Emanuele NV, for the VADT Study Group. Long-term follow-up of intensive glycemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia, 61(2):295-299, (Feb) 2018.
 172. Stroupe KT, Stelmack JA, Tang XC, Wei Y, Sayers S, **Reda DJ**, Kwon E, Massof RW. For the LOVIT II Study Group. Economic evaluation of low-vision rehabilitation for veterans with macular diseases in the Department of Veterans Affairs. JAMA Ophthalmol, 136(5):524-531, (May) 2018.
 173. Wolpaw JR, Bedlack RS, **Reda DJ**, Ringer RJ, Banks PG, Vaughan TM, Heckman SM, McCane LM, Carmack CS, Winden S, McFarland DJ, Sellers EW, Shi H, Paine T, Higgins DS, Lo AC, Patwa HS, Hill KJ, Huang GD, and Ruff RL. Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. Neurology, 91(3):e258-e267, (Jul 17) 2018.
 174. Davis SN, Duckworth W, Emanuele N, Hayward RA, Wiitala WL, Thottapurathu L, **Reda DJ** and Reaven PD for the Investigators of the Veterans Affairs Diabetes Trial. Effects of severe hypoglycemia on cardiovascular outcomes and death in the Veterans Affairs Diabetes Trial. Diabetes Care, 42(1):157-163, (Jan) 2019.
 175. Shinawi MS, Alpern R, Toomey R, Dannenfeldt DS, **Reda DJ**, Blanchard M. Birth defects among 788 children born to Gulf War veterans based on physical examination. J Occ Env Med, 61(4):263-270, (Apr) 2019.
 176. Collins EG, Jelinek C, O'Connell S, Butler J, **Reda D**, Laghi F. The effect of breathing retraining using metronome-based acoustic feedback on exercise endurance in COPD: a randomized trial. Lung, 197 (2):181-188, (Apr) 2019.
 177. Blanchard M, Molina-Vicenty HD, Stein PK, Li X, Karlinsky J, Alpern R, **Reda DJ**, Toomey R. Medical correlates of chronic multisymptom illness in Gulf War veterans. Am J Med, 132(4):510-518, (Apr) 2019.
 178. Toomey R, Alpern R, **Reda DJ**, Baker DG, Vasterling JJ, Blanchard M, Eisen SA, Mental health in spouses of U.S. Gulf War veterans. Psychiatry Res, 275:287-295, (May) 2019.
 179. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, **Reda DJ**, McCarren M, Duckworth WC, Hayward RA for the VADT Investigators. Intensive glucose control in patients with type 2 diabetes: 15-year follow-up. N Engl J Med, 380:2215-24, (Jun 6) 2019.
 180. Agrawal L, Azad N, Bahn GD, Reaven PD, Hayward RA, **Reda DJ**, and Emanuele NV, for the VADT Study Group. Intensive glycemic control improves long-term renal outcomes in type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care, 42:e181-e182, (Nov) 2019.

181. Deuschl G, Follett KA, Luo P, Rau J, Weaver FM, Paschen S, Steigerwald F, Tonder L, Stoker V, and **Reda DJ**. Comparing two randomized deep brain stimulation trials for Parkinson's disease. *J Neurosurg*, 132:1376-1384, (May) 2020.
182. Banerjee S, Luo P, **Reda DJ**, Latif F, Hastings JL, Armstrong EJ, Bagai J, Abu-Fadel M, Baskar A, Kamath P, Lippe D, Wei Y, Scrymgeour A, Gleason TC, and Brilakis ES. Plaque regression and endothelial progenitor cell mobilization with intensive lipid elimination regimen (PREMIER). *Circ Cardiovasc Interv*. 13(8):e00893, (Aug) 2020.
183. Bhaumik DK, Shi H, **Reda DJ** and Sinha BK. Generalized confidence interval for an agreement between raters. *Statist Med*, 40(9):2230-38, (Apr 30) 2021.
184. Brawman-Mintzer O, Tang XC, Bizien M, Harvey PD, Horner MD, Arciniegas DB, Raskind M, Johnson-Greene L, Martineau RJ, Hamner M, Rodriguez-Suarez M, Jorge RE, McGarity S, Wortzel HS, Wei Y, Sindowski T, Mintzer J, Kindy AZ, Donovan K, **Reda D**. Rivastigmine transdermal patch treatment for moderate to severe cognitive impairment in veterans with traumatic brain injury (RiVET Study): a randomized clinical trial. *J Neurotrauma*, 38(14):1943-1952, (Jul 15) 2021.
185. Leehey DJ, Carlson K, **Reda DJ**, Craig I, Clise C, Conner TA, Agarwal R, Kaufman JS, Anderson RJ, Lammie D, Huminik J, Polzin L, McBurney C, Huang GD, Emanuele NV. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomized controlled trial. *BMJ Open*, 11:8:e053019, (Aug 16), 2021.
186. Azad N, Agrawal L, Bahn G, Emanuele NV, Reaven PD, Hayward R, **Reda D**; for the VADT Study Group. Eye outcomes in Veteran Affairs Diabetes Trial (VADT) after 17 years. *Diabetes Care*, 44(10):2397-2402, (Oct) 2021.
187. Toomey R, Alpern RE, White AJ, Li X, **Reda DJ**, Blanchard MS. Physical health, behavioral and emotional functioning in children of gulf war veterans. *Life Sci*, 282:119777, (Oct) 2021.
188. Toomey R, Alpern RE, **Reda DJ**, Baker DG, Vasterling JJ, Blanchard MS, Eisen SA. A cohort study of neuropsychological functioning in spouses of U.S. Gulf War veterans. *Life Sci*, 284: 119894, (Aug 25) 2021.
189. Raghavan S, Josey K, Bahn G, **Reda D**, Basu S, Berkowitz SA, Emanuele N, Reaven P and Ghosh D. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control. *Ann Epidemiol*, 65 (1):101-108, (Jan) 2022.
190. Rothlind JC, York MK, Luo P, Carlson K, Marks, Jr. WJ, Weaver FM, Stern M, Follett KA, Duda JE, **Reda DJ** for the CSP 468 study group. Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease. *Parkinsonism Relat Dis*, 95: 23-27, (Feb) 2022.
191. Sawitzke AD, Jackson CG, Carlson K, Bizien MD, Leiner M, **Reda DJ**, Sindowski T, Hanrahan C, Spencer RG, Kwok CK, Lee SJ, Hose K, Robin L, Cain DW, Taylor MD, Bangerter N, Finco M, Clegg DO. Effect of pulsed low-intensity ultrasonography on symptom relief and tibiofemoral articular cartilage thickness among Veterans Affairs enrollees with knee osteoarthritis. A randomized clinical trial. *JAMA Network Open*. 5(3): e220632, (Mar 8) 2022.
192. Donovan JL, Jepson M, Rooshenas L, Paramasivan S, Mills N, Elliott D, Wade J, Reda D, Blazeby JM, Moghanaki D, Hwang ES and Davies L. Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway

- with enrolment shortfalls—to identify previously hidden barriers and improve recruitment. *Trials*, 23:258, (April 4) 2022.
193. Johnson S, Gerding DN, Li X, **Reda DJ**, Donskey CJ, Gupta K, Goetz MB, Climo MW, Gordin FM, Ringer R, Johnson N, Johnson M, Calais LA, Goldberg AM, Ge L, Haegerich T. Defining optimal treatment for recurrent *Clostridioides difficile* infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence. *Contemp Clin Trials*, 116: 106754, (May 2022).
 194. Shi H, Sahu S, **Reda DJ**, Sinha BK, Bhaumik DK. Agreement between raters for hierarchical designs with repeated measurements. *Gujarat Journal of Statistical and Data Science*, 38(1):132-150, (July) 2022.
 195. Golier JA, Li X, Bizien M, Hurley RA, Bechard BW, Kimbrell T, Flory JD, Baker DG, Yehuda R, **Reda DJ**. Efficacy and safety of mifepristone in the treatment of male US Veterans with posttraumatic stress disorder: A Randomized Clinical Trial. *JAMA Network Open*. 2023;6(5):e2310223. doi:10.1001/jamanetworkopen.2023.10223, May 9, 2023.
 196. Moghanaki D, et al. Protocol for the Veterans Affairs Cooperative Studies Program Study #2005: A Phase III Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). In press, *CHEST Pulmonary*, 2023.

BOOKS and BOOK CHAPTERS

1. Materson BJ, Freis ED, **Reda D**, and the Veterans Administration Cooperative Study Group on Antihypertensive Agents. "Dose-Dependent Metabolic Perturbations by Hydrochlorothiazide and Propranolol," in *Diuretics Chemistry, Pharmacology, and Clinical Applications*, Puschett, JB and Greenberg, A (Eds.) Elsevier Science Publishing Co., Inc., New York, pp. 251-253, 1984.
2. Materson BJ, Lakshman MR, Nunn S, **Reda D** and Cushman WC for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. "Plasma Lipid and Lipoprotein Profiles in Response to Six Antihypertensive Drugs and Placebo." Presented at the Fourth International Conference on Diuretics, October 11-16, 1992, Boca Raton, FL. Published in *Diuretics IV: Chemistry, Pharmacology and Clinical Applications*, Puschett, JB and Greenberg, A (Eds.) Elsevier Science Publishing Co., Inc., New York, pp. 511-513, 1993.
3. Jonler M, Bruskevitz RC, **Reda DJ** and Wasson JH. "Impact of Prostatectomy on the Natural History of Benign Prostatic Hyperplasia", in *Epidemiology of Prostate Disease*, Garraway, M (ed.), Springer-Verlag, Berlin, pp. 153-164, 1995.
4. Materson BJ and **Reda DJ**. "Department of Veterans Affairs Cooperative Study on Monotherapy of Hypertension", in *Clinical Trials in Hypertension*, Black (Ed.) Marcel Dekker, Inc., New York, pp. 283-312, 2001.
5. Reda, D. *A Comparison of Sequential Procedures to Monitor Recruitment Rates in Clinical Trials*, University of Illinois at Chicago, Health Sciences Center, 2001.
6. Gibbs JO, **Reda DJ**, Henderson WG, Dunlop DD, Jonasson O, Neumayer LA. "Clinical Research", in *Nyhus and Condon: Hernia (Fifth Edition)*, Fitzgibbons and Greenburg (Eds.), Lippincott Williams and Wilkins, Philadelphia, PA, pp. 575-610, 2002.

7. Jonasson O and **Reda D.** “General Surgery”, in Textbook of Clinical Trials (Second Edition), Machin, Day and Green (Eds.), John Wiley and Sons, Ltd., London, UK, pp. 543-552, 2006.
8. Weaver FM, Follett KA, **Reda DJ** and Hur K. “Conducting Clinical Trials of Deep Brain Stimulation in Parkinson’s Disease”, in Deep Brain Stimulation for Parkinson’s Disease, Baltuch GH and Stern MB (Eds.), Informa Healthcare USA, Inc, pp. 299-322, 2007.
9. Itani K and **Reda D.J.** (eds.). Clinical Trials Design in Invasive Operative and Non Operative Procedures, Springer, 2017.
10. **Reda, D.J.**, “Clinical Phases of Device and Drug Evaluation with Emphasis on Early Phase Trials”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 41-50.
11. **Reda, D.J.**, “Overview of the Randomized Clinical Trial and the Parallel Group Design”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 51-58.
12. **Reda, D.J.**, “Non-inferiority and Equivalence Trials”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 59-68.
13. **Reda, D.J.**, “Factorial Designs”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 69-77.
14. **Reda, D.J.**, “Cross-over Trials”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 79-86.
15. Huang, G.D. and **Reda D.J.**, “Designing Clinical Trials For Quality and Impact: the Department of Veterans Affairs Approach to Developing a Cooperative Study”, in Clinical Trials Design in Operative and Non Operative Invasive Procedures. 2017, Springer. p. 459-470.

BOOK REVIEWS:

1. **Reda DJ.** Statistical Aspects of the Design and Analysis of Clinical Trials (revised edition), Everitt BS and Pickles A. Statist. Med., 25:2867-8, 2006.

LETTERS TO THE EDITOR:

1. Materson BJ, **Reda DJ** and Cushman WC. Reply: Single-drug therapy for hypertension in men. N Engl J Med, 329(14):1045-1045, (Sep 30) 1993
2. Wasson JH, **Reda DJ**, Bruskewitz RC and Oesterling JE. Reply: Treatment of benign prostatic hyperplasia. N Engl J Med, 332(25):1716-1717, (Jun 22) 1995
3. Clegg DO and **Reda DJ.** Reply: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum, 40(10):1912-1912, 1997.
4. Flanagan, RC, **Reda, DJ**, Wasson JH, Anderson RJ, Abdellatif M and Bruskewitz RC. Reply: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative Study. J Urol, 161(2):614-614, 1999.
5. Preston RA, Materson BJ, **Reda DJ**, and Williams DW. Reply: Renin profiling to predict response to antihypertensive therapy. JAMA, 281(9):793-794, (Mar 3) 1999.

6. Preston RA, Materson BJ, **Reda DJ**, Williams DW: Reply: Placebo-controlled trials are unethical in clinical hypertension research. Arch Int Med, 160(20):3168-3169; (Nov 13) 2000.
7. Battistone MJ [**Reda**]. Reply: Radiographic diagnosis of sacroiliitis – are sacroiliac views really better? J Rheumatol, 28(1):212-214; (Jan) 2001.
8. Singh BN, Singh, SN, **Reda DJ**. Reply: Amiodarone versus sotalol for atrial fibrillation. N Engl J Med, 353(6):629-630, (Aug 11) 2005.
9. Clegg DO and **Reda DJ**. Reply: Glucosamine and Chondroitin Sulfate for knee osteoarthritis. N Engl J Med, 354(20):2185-2185, (May 18) 2006.
10. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, **Reda DJ**, Williams HJ, Clegg, DO. Reply: Methodology and statistical analysis in the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum, 60(11): 3515-3516, (Nov) 2009.

PRESENTATIONS AND ABSTRACTS:

1. Beck V and **Reda D**. Efficacy of liquid crystal thermography for vein assessment in outpatients receiving antineoplastic agents - preliminary results. 1982 Nursing Research Conference; Chicago, IL.
2. Heringa P, Lawson L and **Reda D**. The effect of a structured education program on cognitive and psychomotor skills of patients using beclomethasone dipropionate aerosol - preliminary results. 1982 Respiratory Nursing Conference, Chicago, IL
3. Materson BJ, Freis ED, **Reda DJ** for the VA Cooperative Study Group on Antihypertensive Agents. Thiazide treatment of mild hypertension in the aged. Presented at the 6th Annual Meeting of the Southeastern Pharmacology Society, October 24, 1985, Key Biscayne, FL. J Clin Pharmacol, 25:633, 1985.
4. Materson BJ, Freis ED, **Reda DJ** for the VA Cooperative Study Group on Antihypertensive Agents. Step-2 therapy of mild hypertension in the aged. Presented at 6th Annual Meeting of the Southeastern Pharmacology Society, October 24, 1985, Key Biscayne, FL. J Clin Pharmacol, 25:633, 1985.
5. Goldstein G, Kanagy M, Materson BJ, Freis ED, **Reda D**, et al. Neuropsychological effects of five antihypertensive agents. Presented at a meeting of the International Neuropsychological Society, February 8, 1986, Denver, CO. J Clin Exp Psychol, 7:648-649, 1985.
6. **Reda DJ** for the VA Cooperative Study Group on Antihypertensive Agents. Data management and quality control in the Veterans Administration Cooperative Study 213: treatment of mild hypertension in the aged. Presented at the 7th Annual Meeting of the Society for Clinical Trials, May 13, 1986, Montreal, Can. Controlled Clinical Trials, 7:256-256 1986.
7. Cushman W, Materson B, Goldstein G, **Reda D**, Nunn S, Freis E, et al. Sexual dysfunction in elderly hypertensive men: effects of antihypertensive agents in a Cooperative Study. Presented at the National Conference on High Blood Pressure Control, Las Vegas, NV, April 25, 1987.
8. Keller AM, Berger DJ, Zubkoff M and the VA Cooperative TURP Group [**Reda**]. Cost-effectiveness In a VA Cooperative Study of prostate surgery for benign prostatic hyperplasia in elderly men. Presented at the Eighth Annual Meeting of the Society for Clinical Trials, May 19, 1987, Atlanta, GA. Controlled Clinical Trials, 8:292-293, 1987.

9. **Reda DJ** for the VA Cooperative TURP Group. Integration of a cost-effectiveness component into the VA Cooperative Study 246: prostatic surgery for moderately symptomatic benign prostatic hyperplasia in elderly men. Presented at the Eighth Annual Meeting of the Society for Clinical Trials, May 19, 1987, Atlanta, GA. Controlled Clinical Trials, 8:305-305, 1987.
10. Khatri I, Materson BJ, Freis ED, **Reda D**. Blood pressure response to low and high dose thiazide diuretic for the isolated systolic hypertension of the elderly. Presented at the Council for High Blood Pressure Research 41st Annual Fall Conference and Scientific Sessions, October 13-16, 1987, New Orleans, LA. Hypertension, Vol 10, #3:370, 1987.
11. Materson BJ, Cushman WC, Goldstein G, **Reda DJ**, Freis ED and the Veterans Administration Cooperative Study Group on Antihypertensive Agents. Blood pressure reduction in mildly hypertensive elderly patients does not impair cognitive or behavioral function. Presented at the 12th Scientific Meeting of the International Society of Hypertension, Kyoto, Japan, May 23, 1988.
12. **Reda DJ**, Hsu Y-L, Hong D and the VA Cooperative TURP Group. Microcomputer - based data management and statistical analysis in a va cooperative study. Presented at the Ninth Annual Meeting, Society for Clinical Trials, May 23, 1988, San Diego, CA. Controlled Clinical Trials, 9:263-263, 1988.
13. Emanuele MA, Tentler J, **Reda D**, Kirsteins L, Emanuele NV and Lawrence AM. The effect of in vitro ethanol exposure on stimulated LHRH release from perfused rat hypothalami. Presented at the Endocrine Society Meetings, Orleans, LA, June 10, 1988.
14. Gottdiener JS, **Reda DJ**, Notargiacomo A, Materson BJ. Racial difference in prevalence and severity of LVH in men with mild-moderate hypertension: echocardiographic assessment of a multicenter population. Presented at the Fourth Scientific Meeting of the American Society of Hypertension, May 10, 1989, New York, NY. Am J Hypertension, 2:45(2), 1989.
15. Fye C, Koontz D, **Reda D**, Lizano B, Haakenson C and Materson B. Site visit methodology in a VA Cooperative Study. Presented at the Tenth Annual Meeting of the Society for Clinical Trials, May 16, 1989, Minneapolis, MN. Controlled Clinical Trials, 10:337-338, 1989.
16. Azad N, Emanuele NV, Tentler J, **Reda D**, Kirsteins L and Lawrence AM. In vitro immunoneutralization of hypothalamic prolactin reduces basal and stimulated LHRH and B endorphin release from hypothalamus. Presented at the Endocrine Club Meeting, Chicago, IL, May 15, 1989.
17. Gottdiener JS, Notargiacomo A, **Reda DJ** and Materson BJ. Prevalence and severity of LVH in men with mild-moderate hypertension: echocardiographic assessment of a multicenter population. Presented at the 62nd Scientific Sessions of the American Heart Association, November 15, 1989, New Orleans, LA. Circulation, 80:4(s):II-535, 1989.
18. Ramirez EA and the Veterans Administration Cooperative Study Group Antihypertensive Agents [**Reda**]. Effect of treatment on cognitive and behavioral functions of elderly hypertensives. Presented at ACP Meetings, San Juan, PR, October, 1990.
19. Gottdiener J, **Reda D**, Notargiacomo A, and Materson B. Comparison of monotherapy on LV mass regression in mild-to-moderate hypertension: echocardiographic results of a multicenter trial. Presented at American College of Cardiology 40th Annual Scientific Session, Atlanta, GA, March 3-7, 1991. JACC, 17:2:178A, 1991.

20. Goldstein G for the DVA Cooperative Study Group on Antihypertensive Agents [**Reda**]. Practice effect phenomena in a national hypertension study. Presented at the 1991 American Psychological Association Convention. Clinical Neuropsychologist, 5:263, 1991.
21. Stelmack J, **Reda D** and Finley P. Predicting reading performance of geriatric patients post exudative maculopathy. Presented at the 1991 Annual ARVO Meetings, April 29, 1991, Sarasota, FL. Investigative Ophthalmology and Visual Science, 32:4:815, 1991.
22. VA Cooperative Study Group on Antihypertensive Agents [**Reda**]. VA Cooperative Study #290: monotherapy of hypertension. Presented at the American Society of Hypertension Sixth Scientific Meetings, May 17, 1991, New York, NY.
23. Gottdiener JS, Notargiacomo A, **Reda D**, and Materson B. Adverse Effects of atenolol on left ventricular afterload in mild-to-moderate hypertension: echocardiographic results of a multi-center monotherapy trial. Presented at the American Society of Hypertension Sixth Scientific Meetings, May 1991, New York, NY. Am J Hypertension, 4:5(2):56A, 1991.
24. Cushman WC, for the VA Cooperative Study Group on Antihypertensive Agents [**Reda**]. Antihypertensive therapy: VA Trials on hypertension in the elderly. Presented at the 21st Annual Meeting of the American Aging Association, Denver, CO, October 9-12, 1991.
25. Massie BM, Cushman WC, **Reda DJ**, Materson BJ for the VA Cooperative Study Group on Antihypertensive Agents. Monotherapy of hypertension. results of major subgroup analyses at one year. Presented at the 64th Scientific Sessions of the American Heart Association, November 11, 1991, Anaheim, CA. Circulation, 84:Suppl.II:II-137, 1991.
26. Cushman WC, **Reda DJ**, Materson BJ, Massie BM, and Hamburger RJ for the VA Cooperative Studies Group on Antihypertensive Agents. Comparison of monotherapy with different classes of drugs on systolic and diastolic blood pressure reduction in hypertension. Presented at the American Society of Hypertension Seventh Scientific Meeting, May 9, 1992, New York, NY. Am J Hypertension, 5:7A, 1992.
27. Gottdiener J, **Reda D**, Notargiacomo A, Materson B, VA Cooperative Study Group on Antihypertensive Agents. Racial differences in cardiac effects of mild-to-moderate hypertension: echocardiographic assessment of a large multi-center population. Presented at the American Society of Hypertension Seventh Scientific Meeting, May 7, 1992, New York, NY. Am J Hypertension, 5:A07, 1992.
28. Ramirez EA and the Veterans Affairs Cooperative Study Group on Antihypertensive Agents [**Reda**]. Laboratory changes with antihypertensive drugs. Presented at the Third Annual Scientific Business Meeting Puerto Rico Chapter American College of Cardiology, March, 1992.
29. Wasson J for the Veterans Affairs Cooperative Study Group [**Reda**]. "The one year effectiveness of transurethral resection (TURP) versus watchful waiting (WW) in men with moderately symptomatic benign prostatic hyperplasia (BPH). Presented at the Society of General Internal Medicine 15th Annual National Meeting, April 29, 1992, Washington, DC.
30. Fihn S for the Veterans Affairs Cooperative Study #246 [**Reda**]. Genitourinary factors associated with poor outcome following transurethral resection (TURP) or watchful waiting (WW) for benign prostatic hyperplasia (BPH). Presented at the Society of

- General Internal Medicine 15th Annual National Meeting, April 29, 1992, Washington, DC.
31. Bruskewitz R [**Reda**]. Veterans Administration randomized benign prostatic hypertrophy study. Presented at the American Urological Association 87th Annual Meeting, May 12, 1992, Washington, DC.
 32. Clegg DO and **Reda DJ**. Measurement of disease severity in the VA cooperative study of sulfasalazine for the treatment of ankylosing-spondylitis. Arthritis and Rheumatism, 35:9:S353, 1992.
 33. Gottdiener JS, **Reda DJ**, Notargiacomo AV, Materson BJ, VA Cooperative Study Group on Antihypertensive Agents. The importance of obesity to the cardiac structural and functional effects of mild-to-moderate hypertension. Presented at the 65th Scientific Sessions of the American Heart Association, November 16-19, 1992, New Orleans, LA. Circulation, 86:4:2678, 1992.
 34. Cushman WC, Nunn SL, Lakshman MR, **Reda DJ** and Materson BJ for the VA Cooperative Study Group on Antihypertensive Agents. Monotherapy of hypertension: effects of six classes of drugs and placebo on plasma lipids. Presented at the American Society of Hypertension Eighth Scientific Meeting, New York, May 1993. Am J Hypertens 6:9A, 1993.
 35. Clegg DO and **Reda DJ** for the Department of Veterans Affairs Cooperative Studies Program. Comparison of sulfasalazine and placebo for the treatment of ankylosing spondylitis. Presented at the 56th Annual Meeting of the American College of Rheumatology, November 9, 1993, San Antonio, TX. Arthritis and Rheumatism, 36:9:S73, 1993.
 36. Hughes SD, Clegg DO and **Reda DJ** Correlation of sedimentation rate, C-reactive protein and spondylitis functional index in a multicenter seronegative spondyloarthropathy study. Presented at the 56th Annual Meeting of the American College of Rheumatology, November 10, 1993, San Antonio, TX.
 37. Preston RA, Materson BJ, **Reda DJ** for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Comparison of urinary protein excretion among six antihypertensive agents and placebo. Presented at the American Society of Hypertension Ninth Scientific Meeting, New York, May 1994. Am J Hypertens, 7(2):34A, 1994.
 38. Materson BJ, Preston RA, **Reda DJ** for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Results of combination antihypertensive therapy after failure of each of the components. Presented at the American Society of Hypertension Ninth Scientific Meeting, New York, May 1994. Am J Hypertens, 7(2):34A, 1994.
 39. Materson BJ, Preston RA, **Reda DJ** for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Presented at the American Society of Hypertension Ninth Scientific Meeting, New York, May 1994. Am J Hypertens, 7(2):34A, 1994.
 40. Bruskewitz RC for the Veterans Affairs Cooperative Study Group on Transurethral Resection [**Reda**]. Predictions of failure for watchful waiting strategy for BPH. Presented at the AUA Eighty-Ninth Annual Meeting, May 14-19, 1994, San Francisco, CA. J Urol, 151:267A, 1994.

41. Massie BM, Der E, Gottdiener J, Materson B, and **Reda D** for the VA Monotherapy of Hypertension Study Group. Contrasting effects of demographic factors on ECG and echocardiographic indices of left ventricular hypertrophy. Presented at the American Heart Association 67th Scientific Sessions, November 17, 1994, Dallas, TX. Circulation, 90:4(2):I-26, 1994.
42. Gottdiener JS, **Reda DJ**, Williams DW, Massie BM, Materson BJ for the VA Cooperative Study Group on Antihypertensive Agents. Regression of left ventricular mass with monotherapy of hypertension: interaction of drug with systolic blood pressure, age, race, and weight. Presented at the American Heart Association 67th Scientific Sessions, November 16, 1994, Dallas, TX. Circulation, 90:4(2):I-565, 1994.
43. Clegg DO, **Reda DJ**, Weisman MH, Cush JJ, Vasey FP, Schumacher HR, Budiman-Mak E, Taylor TT, Cannon GW, Blackburn WD, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald M, Higashida J, and Silverman SL for the Department of Veterans Affairs Cooperative Studies Program. Comparison of sulfasalazine and placebo for the treatment of Reiter's Syndrome. Presented at the American College of Rheumatology 58th Annual Scientific Meeting, October 24, 1994, Minneapolis, MN. Arthritis and Rheumatism, 37:9(S):206, 1994.
44. Clegg DO and **Reda DJ** for the Department of Veterans Affairs Cooperative Studies Program. Comparison of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous arthritis. Presented at the American College of Rheumatology 58th Annual Scientific Meeting, October 24, 1994, Minneapolis, MN. Arthritis and Rheumatism, 37:9(S):206, 1994.
45. Papademetriou V, Der E, Gottdiener J, Materson B, **Reda D**, Massie B for the VA Monotherapy of Hypertension Study Group. Effect of 6 antihypertensive drugs on ECG left ventricular hypertrophy. Presented at the American College of Cardiology 1995 Meetings, New Orleans, LA, March 20, 1995. J Am Coll Cardiol, (special issue) 122A, February, 1995.
46. Aurigemma GP, Gottdiener JS, Gaasch WH, Williams D, Jamal Z, **Reda DJ**, Materson BJ. Ventricular and myocardial function following regression of hypertensive left ventricular hypertrophy. Presented at the American College of Cardiology 1995 Meetings, New Orleans, LA, March 21, 1995. J Am Coll Cardiol, (special issue) 251A, February, 1995.
47. Cushman WC, **Reda DJ**, Materson BJ, and Perry HM for the VA Cooperative Study Group on Antihypertensive Agents. Stroke belt as a predictor of antihypertensive efficacy with single-drug therapy. Presented at the American Society of Hypertension Tenth Scientific Meeting, May 18, 1995. Am J Hyperten, 8:4 (2), 1995.
48. **Reda D**, Anderson R, Abdellatif M, Williams D, and Clegg D. Longitudinal analysis of binary data in the V.A. Cooperative Study of sulfasalazine for the treatment of seronegative spondyloarthropathies. Presented at the Society for Clinical Trials 16th Annual Meeting, May 1, 1995, Seattle, WA. Controlled Clinical Trials, 16:3S:90S, 1995.
49. Henderson W, **Reda D**, Wasson J, Bruskevitz R, Keller A, Johnson D, Zubkoff M, Barrett L and Hynes D. Cost-effectiveness analysis in the V.A. Cooperative Study of transurethral resection of the prostate vs. watchful waiting in benign prostatic hyperplasia. Presented at the Society for Clinical Trials 16th Annual Meeting, May 2, 1995, Seattle, WA. Controlled Clinical Trials, 16:3S:45S, 1995.

50. Anderson S, Abdellatif M, Schreiner S, McDonell M, **Reda D**, and Fihn S. Information system for a multi-hospital study using optical scanning and hospital database downloads. Presented at the Society for Clinical Trials 16th Annual Meeting, May 1, 1995, Seattle, WA. Controlled Clinical Trials, 16:3S:76S, 1995.
51. McDonell MB, Schleyer AM, Fincke G, Orlander J, Sauvigne A, **Reda D** and Fihn SD for the ACQUIP Investigators. Reliability and responsiveness of a patient satisfaction questionnaire. Presented at the 18th Annual Meeting of the Society of General Internal Medicine, May 4-6, 1995, San Diego, CA. J Gen Intern Med, 10:4(S):73, 1995.
52. McDonell MB, Schleyer AM, **Reda D**, Fincke G, Orlander J, Sauvigne A, and Fihn SD for the ACQUIP Investigators. Continuity of care as a determinant of patient satisfaction. Presented at the 18th Annual Meeting of the Society of General Internal Medicine, May 4-6, 1995, San Diego, CA. J Gen Intern Med, 10:4(S):73, 1995.
53. Schleyer AM, Paden GR, McDonell MB, **Reda D** and Fihn SD for the ACQUIP Investigators. Performance of the MHI-5 as a screen for depression in VA outpatients. Presented at the 18th Annual Meeting of the Society of General Internal Medicine, May 4-6, 1995, San Diego, CA. J Gen Intern Med, 10:4(S):48, 1995.
54. Schleyer AM, McDonell MB, **Reda D**, and Fihn SD for the ACQUIP Investigators. Does a patient's general satisfaction with care reflect satisfaction with care for specific conditions? Presented at the 18th Annual Meeting of the Society of General Internal Medicine, May 4-6, 1995, San Diego, CA. J Gen Intern Med, 10:4(S):79, 1995.
55. Tu S, McDonell D, **Reda D**, and Fihn SD. The seattle obstructive lung disease questionnaire is a sensitive and reliable functional status measure. Presented at the 18th Annual Meeting of the Society of General Internal Medicine, May 4-6, 1995, San Diego, CA. J Gen Intern Med, 10:4(S):84, 1995.
56. Clegg DO and **Reda DJ** for the Department of Veterans Affairs Cooperative Studies Program. Comparison of sulfasalazine and placebo for the treatment of axial, oligoarticular and polyarticular manifestations of the seronegative spondyloarthropathies. Presented at the American College of Rheumatology 59th National Meeting, San Francisco, CA, October 25, 1995. Arthritis and Rheumatism, 38:9:S349, 1995.
57. Gottdiener JS, **Reda DJ**, Williams DW, Materson BJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Left atrial size in hypertension: influence of obesity, race and age. Presented at the American Heart Association 68th Scientific Sessions, Anaheim, CA, November 16, 1995. Circ, 92:8:I-802, 1995.
58. Sadler DB, Aurigemma GP, Williams DW, **Reda D**, Gottdiener JS, Materson BJ. Hypertensives with concentric remodeling have depressed chamber, pump and myocardial function in the absence of left ventricular hypertrophy. Presented at the American Heart Association 68th Scientific Sessions, Anaheim, CA, November 14, 1995. Circ, 92:8:I-268, 1995.
59. Bruskewitz RC, **Reda DJ**, Wasson J and Barrett L. Tests which predict outcome following transurethral resection of the prostate. Presented at the American Urological Association meeting, May 7, 1996, Orlando, FL. J Urol, 155:5:573A, 1996.
60. Schleyer AM, McDonell MB, Paden GR, **Reda DJ**, Fihn SD for the ACQUIP Investigators. Periodic screening for depression in the ambulatory care setting. Presented at the 19th Annual Meeting of the Society of General Internal Medicine, May 2-4, 1996, Washington DC. J Gen Intern Med, 10:4(S):85, 1996.

61. Spertus JA, Bradley KA, McDonell MB, Fihn SD and **Reda DJ** for the ACQUIP Investigators. Alcohol use and functional status in patients with heart disease. Presented at the 19th Annual Meeting of the Society of General Internal Medicine, May 2-4, 1996, Washington DC. J Gen Intern Med, 10:4(S):89, 1996.
62. Spertus JA, McDonell MB, **Reda DJ**, Fihn SD for the ACQUIP Investigators. Depression and the functional status of patients with heart disease. Presented at the 19th Annual Meeting of the Society of General Internal Medicine, May 2-4, 1996, Washington DC. J Gen Intern Med, 10:4(S):89, 1996.
63. Abdellatif M, Williams D and **Reda D**. Accessing data from external centralized sources to enhance analysis of a completed clinical trial. Presented at the 17th Annual Meeting of the Society for Clinical Trials, May 7, 1996, Pittsburgh, PA. Controlled Clinical Trials, 17:2s:118s-119s, 1996.
64. **Reda DJ**, Clegg DO and Anderson RJ. Analyzing treatment effects at the end of follow-up -are we missing important information?: lessons from the VA Cooperative Study of sulfasalazine for the treatment of seronegative spondyloarthropathies. Presented at the 1996 National Scientific Meeting of the American College of Rheumatology, October 21, 1996, Orlando, FL. Arthritis and Rheumatism, 39:9:S256, 1996.
65. Battistone MJ, Manaster BJ, **Reda DJ** and Clegg DO for the Department of Veterans Affairs Cooperative Study for the Treatment of Seronegative Spondyloarthropathies. Radiographic diagnosis of sacroiliitis- are SI views really better? Presented at the 1996 National Scientific Meeting of the American College of Rheumatology, October 20, 1996, Orlando, FL. Arthritis and Rheumatism, 39:9:S206, 1996.
66. Cohen MR, **Reda DJ** and Clegg DO for the Department of Veterans Affairs Cooperative Study for the Treatment of Seronegative Spondyloarthropathies. Sulfasalazine therapy effects a different response in the treatment of cutaneous psoriasis than in psoriatic arthritis. Presented at the 1996 National Scientific Meeting of the American College of Rheumatology, October 21, 1996, Orlando, FL. Arthritis and Rheumatism, 39:9:S256, 1996.
67. Kaufman J and **Reda D** for VA Cooperative Study #392. A comparison of subcutaneous (SC) and intravenous (IV) administration of recombinant human erythropoietin (rHeEPO) in hemodialysis (HD) patients. Presented at the American Society of Nephrology 29th Annual Meeting & Scientific Exposition, November 3, 1996, New Orleans, LA. J Am Soc Nephrology, 7:9:1450, 1996.
68. Kaufman J, **Reda D**, Goldfarb D, Kleinman J and Vaamonde C for DVA Cooperative Study #392. Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin (rHuEPO). Presented at the American Society of Nephrology 29th Annual Meeting & Scientific Exposition, November 3, 1996, New Orleans, LA. J Am Soc Nephrology, 7:9:1450, 1996.
69. Aurigemma GP, Williams D, **Reda DJ**, Gaasch WH, Materson BJ. Midwall mechanics following LV mass regression in hypertensives. Presented at the American Heart Association 69th Scientific Sessions, November, 1996. Circ, 94:8:I-26 - I-27.
70. Battistone MJ, Manaster BJ, **Reda D** and Clegg DO. Prevalence of sacroiliitis in psoriatic arthritis: new perspectives from the largest cohort reported to date. Presented at the 82nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, December 4, 1996, Chicago, IL.

71. Gottdiener JS, Williams D, **Reda D**, Materson B for the VA Cooperative Study Group on Antihypertensive Agents. Comparison of monotherapy for reduction of left atrial size in mild-to-moderate hypertension: results of a multicenter trial. Presented at the American College of Cardiology 46th Annual Scientific Session, March 19, 1997. JACC, 29:2:487A, 1997.
72. Miller MJ, **Reda DJ**, Clegg DO, Haakenson CM, Abdellatif M and Jones MS. An evaluation of sulfasalazine safety in patients with seronegative spondyloarthropathies. Presented at the 1997 Spring Practice and Research Forum of the American College of Clinical Pharmacy, April 8, 1996, Panama City, FL.
73. Flanigan RC, Wasson J, **Reda D**, Bruskevitz R, Anderson R. Long term follow-up in moderately symptomatic patients with BPH. Presented at the American Urological Association Ninety-Second Annual Meetings, April 15, 1997, New Orleans, LA. J Urol, 157:4:312, 1997.
74. van der Heijde D, **Reda DJ**, Dougados M, Strauss PC and Clegg DO. Effectiveness of sulfasalazine for the axial and peripheral manifestations of sero-spondyloarthropathies: a combined analysis of two large randomized trials. Presented at the 1st Congress of the European Federation of Internal Medicine, October 15-18, 1997, Maastricht, Netherlands. European Journal of Internal Medicine, 8:1(S):90, 1997.
75. Preston RA, Materson BJ, **Reda DJ**, Williams DW, Hamburger RJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Renin profile as a predictor of blood pressure response to antihypertensive therapy in 1292 patients: results of the VA Cooperative Study. Presented at the American Society of Nephrology 30th Annual Meeting, November 3, 1997, San Antonio, TX. J Am Soc Nephrology, 8:9:321A, 1997.
76. Preston RA, Materson BJ, **Reda DJ**, Williams DW, Hamburger RJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Age-race subgroup vs. renin profile as predictors of blood pressure response to antihypertensive therapy in 1292 patients: results of the VA Cooperative Study. Presented at the American Society of Nephrology 30th Annual Meeting, November 3, 1997, San Antonio, TX. J Am Soc Nephrology, 8:9:321A, 1997.
77. Kaufman J, **Reda D** for VA Cooperative Study #392. Subcutaneous (SC) versus intravenous (IV) administration of recombinant human erythropoietin (rHuEpo) in hemodialysis (HD) patients (PTS). Presented at the American Society of Nephrology 30th Annual Meeting, November 4, 1997, San Antonio, TX. J Am Soc Nephrology, 8:9:196A, 1997.
78. van der Heijde D, **Reda DJ**, Dougados M, Strauss PC and Clegg DO. Predictors of response to sulfasalazine for seronegative spondyloarthropathy patients with peripheral arthritis - a combined analysis of two large multi-center randomized trials. Presented at the American College of Rheumatology 61st National Scientific Meeting, November 9, 1997, Washington, DC. Arthritis and Rheumatism, 40:9:S62, 1997.
79. Weinblatt MR, **Reda DJ**, Henderson WG, Giobbie-Hurder A and Williams DW. Sulfasalazine treatment for rheumatoid arthritis: a meta-analysis of 17 randomized trials. Presented at the American College of Rheumatology 61st National Scientific Meeting, November 9, 1997, Washington, DC. Arthritis and Rheumatism, 40:9:S51, 1997.
80. Battistone MJ, Manaster BJ, **Reda DJ** and Clegg DO for the Department of Veterans Affairs Cooperative Study for the Treatment of Seronegative Spondyloarthropathies.

Patterns of sacroiliitis among the spondyloarthropathies--analysis of data from a large multicenter cohort. Presented at the American College of Rheumatology 61st National Scientific Meeting, November 9, 1997, Washington, DC. Arthritis and Rheumatism, 40:9:S65, 1997.

81. Gottdiener JS, Williams DW, **Reda DJ**, Materson BJ. Effects of single drug antihypertensive therapy on left atrial enlargement in hypertension. Presented at the American College of Cardiology 47th Annual Scientific Session, March 31, 1998, Atlanta GA. JACC, 31:2(Sup. A):212A, 1998.
82. Preston RA, Materson BJ, **Reda D**, Williams DW, Hamburger RJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Age-race subgroup vs. renin profile as predictors of blood pressure response to antihypertensive therapy in 1105 patients: results of A VA Cooperative Study. Presented at the 17th Scientific Meeting of the International Society of Hypertension, June 11, 1998, Amsterdam, Netherlands. J Hypertens, 16(S2):S35, 1998.
83. Kaufman JS for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. [**Reda**]. Subcutaneous erythropoietin therapy: efficacy and economic implications. Presented at the conference on Strategies for Influencing Outcomes in Pre-ESRD and ESRD Patients sponsored by American Society of Nephrology, National Institutes of Health, National Kidney Foundation and Renal Physicians Association, June 12-14, 1998.
84. Kaufman J, **Reda D**, Fye C, Goldfarb D, Henderson W, Kleinman J, and Vaamonde C for DVA Coop Study #392. Diagnosis of functional iron deficiency in hemodialysis patients on maintenance erythropoietin (rHuEPO). Presented at the American Society of Nephrology 31st Annual Meeting and Scientific Exposition, October 27, 1998, Philadelphia, PA. J Am Soc Nephrology, 9:213A, 1998.
85. Abdellatif M, Mackay BR and **Reda DJ**. Paradox-based distributed data entry system and centralized data management system. Presented at the Twentieth Annual Meeting of the Society for Clinical Trials, May 4, 1999, Anaheim CA. Controlled Clinical Trials, 20:79S, 1999.
86. Abdellatif M, Anderson R and **Reda DJ**. A SAS macro to automate the building of 2nd and 3rd order interactions of dichotomous variables for constructing hierarchical logistic regression models. Presented at the Twentieth Annual Meeting of the Society for Clinical Trials, May 4, 1999, Anaheim CA. Controlled Clinical Trials, 20:84S, 1999.
87. Materson BJ, Preston RA, **Reda DJ** and Williams D. Placebo-associated blood pressure response and adverse effects. Presented at the 14th Scientific Meeting of the American Society of Hypertension, New York City, NY, May, 1999. Am J Hypertension, 2:42A, 1999.
88. Eisen SA, Kang HK and Murphy F for the VA Cooperative Study Group on Gulf War Veterans' Health [**Reda**]. Update on VA Cooperative Study #458: national health survey of gulf war era veterans and their families, phase III. Presented at the Conference on Federally Sponsored Gulf War Veterans' Illnesses Research, June 24, 1999, Arlington VA.
89. Kaufman J, **Reda D**, Fye C, Goldfarb D, Henderson W, Kleinman J, and Vaamonde C for DVA Coop Study #392. Predictors of erythropoietin (rHuEPO) dose in patients on maintenance hemodialysis. Presented at the American Society of Nephrology 32nd

- Annual Meeting, Miami Beach, FL, November 7, 1999. J Am Soc Nephrology, 10:263A, 1999.
90. Aurigemma GP, Williams D, **Reda DJ**, Gottdiener JS. Ventricular and myocardial function following LV mass reduction in hypertensives: results from the Department of Veterans Affairs Cooperative Study of single drug therapy in hypertension. Presented at the American Heart Association 72nd Scientific Sessions. Circulation, 100:18:I-863, 1999.
 91. Cushman WC, Materson BJ, **Reda DJ**, and Williams DW for the Veterans Affairs (VA) Cooperative study Group on Antihypertensive Agents. Pulse pressure changes with six classes of antihypertensive agents and placebo. Presented at the American Society of Hypertension, New York, NY, May 19, 2000. Am J Hyperten, 13:22A, 2000.
 92. Cushman WC, Materson BJ, **Reda DJ**, and Williams DW for the Veterans Affairs (VA) Cooperative study Group on Antihypertensive Agents. Pulse pressure changes with six classes of antihypertensive agents and placebo in Whites and African Americans by age. Presented at the American Society of Hypertension, New York, NY, May 19, 2000. Am J Hyperten, 13:59A, 2000.
 93. Cushman W, Materson B, **Reda D**, and Williams D. Pulse pressure changes with six classes of antihypertensive agents and placebo. Presented at the International Society of Hypertension, Chicago, IL, August 21-22, 2000. J Hyperten, 18:S38, 2000.
 94. Jackson L, Kang H, Eisen S, Murphy F, Henderson WG and **Reda D**. National Health Survey of Gulf War Era Veterans and Their Families: Phase III participant satisfaction. Presented at the 2001 Conference on Illnesses among Gulf War Veterans, January 24, 2001, Alexandria, VA.
 95. Henderson WG, **Reda D**, Kang H, Jackson L, Murphy F and Eisen S. Participation in the National Health Survey of Gulf War Veterans and Their Families – Phase III Clinical Examinations (VA Cooperative Study No. 458). Presented at the 2001 Conference on Illnesses among Gulf War Veterans, January 24, 2001, Alexandria, VA.
 96. Cushman WC, Materson BJ, **Reda DJ** and Williams D. Pulse pressure changes with six classes of antihypertensive agents and placebo. Presented at the Fourth International workshop on Structure and function of Large Arteries, April 26-28, 2001, Paris, France.
 97. Cushman WC, Materson BJ, **Reda, DJ** and Williams DW. Does obesity influence response to antihypertensive agents? Presented at the American Society of Hypertension 16th Scientific Meeting, San Francisco, CA, May 18, 2001. Am J Hypertension, 14(suppl 1):24A, 2001.
 98. Raisch DW, Fye CL, Sather MR, Gagne W, Henderson WG, **Reda DJ**, Sacks JM, Lederle FA. Impact on quality adjusted life years of enoxaparin for preventing thrombosis among hospitalized patients. Presented at the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 20-23, 2001. Value in Health, 4(2):100,2001.
 99. Abdellatif M, Anderson RG and **Reda DJ**. Automating the building of 2nd and 3rd order interactions and the construction of hierarchical logistic regression models. Presented at the Twenty-seventh Annual SAS Users Group International (SUGI) Conference, April 14-17, 2002, Orlando, FL. Published in the proceedings of the Twenty-seventh Annual SAS Users Group International (SUGI) Conference, Paper 194-27, 2002.
 100. Kleinman JG, Kaufman JS, **Reda DJ**, Williams DW, and Anderson RJ. A model predicting the dose of epoetin in hemodialysis patients. Presented at the American

- Society of Nephrology 35th Annual Meeting, October 30-November 4, 2002, Philadelphia PA. J Am Soc Nephrology, 13:422A, 2002.
101. Singh BN, Singh, SN, **Reda DJ**, Tang XC, Lopez B, Fye CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson A, Lewis Jr. D, Ezekowitz M. Efficacy of sotalol, amiodarone and placebo for cardioversion and maintenance of sinus rhythm in patients with atrial fibrillation. A Veterans Affairs Cooperative Study. Presented at the American Heart Association Scientific Sessions 2003, November 9-12, 2003, Orlando, FL. Circ, 108:IV-508, 2003.
 102. Singh SN, Singh, BN, **Reda DJ**, Tang XC, Fye CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson A, Lewis Jr. HD, Lopez B, and Ezekowitz MD for the SAFE-T Investigators. The effects of amiodarone versus sotalol versus placebo on quality of life measurements and exercise duration in patients with persistent atrial fibrillation. A Veterans Affairs Cooperative Study (SAFE-T). Presented at the American Heart Association Scientific Sessions 2003, November 9-12, 2003, Orlando, FL. Circ, 108:IV-509, 2003.
 103. Davis LE, Eisen SA, Murphy FM, Alpern R, Parks BJ, Blanchard M, **Reda DJ**, King MK, Mithen FA and Kang, HK. Clinical and laboratory assessment of distal peripheral nerves in Gulf War veterans and spouses. Presented at the 56th American Academy of Neurology Annual Meeting, April 28, 2004, San Francisco CA. Neurology, 62 (suppl. 5):A267, 2004.
 104. Collins EG, Langbein WE, Orebaugh C, Bammert C, Hanson K, **Reda D**, Edwards L, and Littooy FN. Cardiovascular training effect associate with polestriding exercise in patients with peripheral arterial disease. Presented at the American Heart Association Scientific Sessions 2004, November 7-10, 2004, New Orleans, LA. Circ, 110:17:III664-III665, 2004.
 105. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski W, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Ellis N, Thottapurathu L, **Reda DJ** and Henderson WG. Coronary artery revascularization prior to major elective vascular surgery does not improve outcome: The Coronary Artery Revascularization Prophylaxis (CARP) Trial. Presented at the American Heart Association Scientific Sessions 2004, November 7-10, 2004, New Orleans, LA. Circ, 111:13:1727, 2005.
 106. Swanson KM, Abdellatif M, Fye C, **Reda D**, Williams D, Harris C and Clegg D. Adverse event reporting and monitoring system for the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Presented at the 26th annual meeting of the Society for Clinical Trials, May 23, 2005. Clinical Trials, 2 (suppl. 1):S49, 2005.
 107. Abdellatif M, Motyka D, Williams D, **Reda D**, Kucmeroski D, Fye C and Clegg D. A data collection and management system for clinical trials in osteoarthritis. Presented at the 26th annual meeting of the Society for Clinical Trials, May 24, 2005. Clinical Trials, 2 (suppl. 1):S72-73, 2005.
 108. Barnhill JG, Fye CL, Williams D, **Reda DJ**, Harris CL and Clegg DO. Product selection in clinical trials of dietary supplements. Presented at the 26th annual meeting of the Society for Clinical Trials, May 24, 2005. Clinical Trials, 2 (suppl. 1):S91, 2005.
 109. Barnhill JG, Fye CL, Williams DW, **Reda DJ**, Harris CL, Clegg DO. Product selection for the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT): Glucosamine. Presented at the 41st annual meeting of the Drug Information Association, June 26-30, 2005, Washington DC. No citation.

110. **Reda DJ**, Hur K, Follett K, Weaver F, Stern M, Harris C. The Design of the VA/NINDS Randomized Clinical Trial of Deep Brain Stimulation for Treatment of Parkinson's Disease. Presented at the 2005 Joint Statistical Meetings, August 9, 2005, Washington, DC.
111. Clegg DO, **Reda DJ**, Harris CL and Klein MA. The efficacy of glucosamine and chondroitin sulfate in patients with painful knee osteoarthritis (OA): The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Presented at the 2005 ACR/ARHP Annual Scientific Meeting, November 14, 2005, San Diego, CA. Arthritis & Rheumatism, 52:S256, 2005.
112. McFalls EO, Ward HB, Moritz TE, Goldman S, Pierpont G, Hattler B, Shrunk K, Larsen G, Littooy F, Krupski W, Henderson WG and **Reda DJ**. Perioperative Myocardial infarction following elective vascular surgery: clinical predictors and outcomes within the Coronary Artery Revascularization Prophylaxis Trial. Presented at the American Heart Association Scientific Sessions, November 14, 2005, Dallas, TX. Circ, 112:17:II-707, 2005.
113. Sharma SC, Tang XC, Singh BN, **Reda DJ**, Singh SN, Harris CL, Fletcher RD, Atwood JE, Jacobson AK, Lewis Jr. HD, Ezekowitz MD and the SAFE-T Investigators. Impact of restoration and maintenance of sinus rhythm on left atrial dimension and left ventricular ejection fraction in atrial fibrillation (VA Cooperative Study #399). Presented at the American Heart Association Scientific Sessions, November 13-16, 2005, Dallas, TX. Circ, 112:17:II-586, 2005.
114. **Reda DJ**, Clegg DO and Shi H for the GAIT Investigators. Planning clinical trials In OA: Relationship between choice of outcome measure, level of symptoms and sample size needed to distinguish treatment effects from placebo effects. Presented at the 10th OARSI World Congress, December 9, 2005, Boston, MA. Osteoarthritis and Cartilage, 13:S15, 2005.
115. Shi H, **Reda DJ** and Clegg DO for the GAIT Investigators. Characteristics of patients who respond to placebo in the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Presented at the 10th OARSI World Congress, December 9, 2005, Boston, MA. Osteoarthritis and Cartilage, 13:S84-85, 2005.
116. Clegg DO, **Reda DJ**, Hooper MH, Moskowitz RW for the GAIT Investigators. Chondroitin sulfate may have differential effects on OA symptoms related to degree of radiographic involvement. Presented at the 10th OARSI World Congress, December 9, 2005, Boston, MA. Osteoarthritis and Cartilage, 13:S76-77, 2005.
117. Ward HB, Kelly RF, Moritz T, Thottapurathu L, Pierpont G, Goldman S, Krupski W, Littooy F, **Reda D**, McFalls EO. Coronary artery bypass is superior to coronary intervention in the prevention of perioperative myocardial infarction during subsequent vascular surgery: The Coronary Artery Revascularization Prophylaxis (CARP) Trial. Presented at the Society for Thoracic Surgery meeting, January 31-February 2, 2006, Chicago, IL. No citation.
118. Weaver, F; Hur, K; Follett, K, Stern M, **Reda D**. Quality of life in persons with Parkinson's disease appropriate for treatment with deep brain stimulation. Presented at the World Parkinson Congress, February 22-26, 2006, Washington DC. Movement Disorders, 21:S151-S151, 2006.
119. Abdellatif M, Alvarado-Garcia N and **Reda DJ**. A randomization method using synchronized web-based and traditional telephone-based systems requiring informed

- consent forms. Presented at the 27th annual meeting of the Society for Clinical Trials, May 23, 2006, Orlando, FL. Clinical Trials, 3:247, 2006.
120. **Reda, DJ.** Results of the “GAIT” Study (Glucosamine-chondroitin Sulfate Arthritis Intervention Trial) and implications for further development of glucosamine and/or chondroitin sulfate for arthritis. Presented at the 42nd Annual Meeting of the Drug Information Association, June 22, 2006, Philadelphia, PA. No citation.
 121. CSP #468 Study Group. Deep brain stimulation vs. best medical therapy for Parkinson’s Disease: patient outcomes from the VA CSP #468 prospective, randomized, multi-center trial. Presented at the Parkinson’s Disease Symposium, October 8, 2006, Chicago, IL. Movement Disorders, 21:1546-1547, 2006.
 122. Emanuele, N; Klein, R; Moritz, T, Anderson R, **Reda D**, Duckworth W, Abaira C. Comparison of dilated fundus examination by ophthalmologists with 7-field stereo fundus photographs in the veterans affairs diabetes trial (VADT). Diabetes, 55:A512-A512, 2006.
 123. Rider J, Ward H, Moritz T, Thottapurathu L, Goldman S, Littooy F, Pierpont G, Larsen G, Santilli S, Shunk K, Rapp J, **Reda D**, Henderson WG and McFalls EO. Preoperative coronary artery revascularization and long-term outcomes in patients with abdominal aortic operations and myocardial ischemia on SPECT: a post-hoc analysis of the CARP trial. Presented at the American Heart Association Scientific Sessions 2006, November 15, 2006, Chicago, IL. Circulation, 114:711-711, 2006.
 124. **Stern, M** for the CSP #468 Study Group. “The effect of parkinson’s disease patient age and stage of illness on quality of life: results of a multi-site randomized trial of best medical therapy vs. deep brain stimulation;” Presented at the 10th International Congress of Parkinson’s Disease and Movement Disorders, October 28-November 2, 2006, Kyoto, Japan.
 125. Clegg DO, Shi H, **Reda DJ**, for the GAIT Investigators. “Osteoarthritis treatment effects for chondroitin sulfate may be more pronounced in mild disease – a GAIT report.” To be presented at the 2006 World Congress on Osteoarthritis, December 9, 2006, Prague, Czech Republic. Osteoarthritis and Cartilage, 14(Supplement B):S163-164, 2006.
 126. **Reda DJ**, Shi H, Clegg DO, for the GAIT Investigators. “Treatment effects are more difficult to detect in osteoarthritis patients who flare at study entry due to increased placebo response – a GAIT report.” To be presented at the 2006 World Congress on Osteoarthritis, December 9, 2006, Prague, Czech Republic. Osteoarthritis and Cartilage, 14(Supplement B):S37-38, 2006.
 127. Matthews R, Anthony T, Kim L, Wang J, Fitzgibbons R, Giobbie-Hurder A, Jonasson O, Itani K, **Reda D**, Neumayer L for the Veterans Affairs Cooperative 456 Studies Program Investigators. Factors associated with post-operative complications and hernia recurrence for patients undergoing inguinal hernia repair: A report from the VA Cooperative Hernia Study Group.
 128. Massof R, Stelmack JP, Mancil GL, Cummings RW, Rinne S, Mancil R, Moran D, Tang C, Stroupe K, **Reda D**. VA Low Vision Intervention Trial (LOVIT): MNREAD Outcomes. Presented at the American Academy of Optometry meeting, October 24, 2007, Tampa FL.
 129. Stelmack JP, Tang C, **Reda D**, Moran D, Rinne S, Mancil R, Mancil GL, Cummings RW, Massof R. Outcomes of the VA Low Vision Intervention Trial (LOVIT) Presented at the American Academy of Optometry meeting, October 24, 2007, Tampa FL.

130. Murray STN, Moritz TE, Pierpont G, Goldman S, Larsen GC, Shunk KA, Wassif HS, Ward HB, **Reda DJ** and McFalls EO. Culprit coronary artery lesions following vascular surgery: Sub-study of the Coronary Artery Revascularization Prophylaxis (CARP) Trial. Presented at the American College of Cardiology 56th Annual Session, March, 2007, New Orleans, LA. J Am Coll Cardiol, 49:217A, 2007.
131. McFalls EO, Ward HB, Pierpont G, Wassif HS, Murray STN, Goldman SG, Larsen GC, Littooy F, Krupski W, Moritz T, **Reda D**, Incidence of left-main stenosis among high risk patients presenting for elective vascular surgery and long-term outcomes. Presented at the American College of Cardiology 56th Annual Session, March 26, 2007, New Orleans, LA. J Am Coll Cardiol, 49:374A, 2007.
132. Garcia, S, Ward, HB, Moritz, T, Littooy F, Goldman S, Pierpont G, Larsen G, **Reda D**, McFalls EO. Long-term outcomes following vascular surgery in patients with multivessel coronary artery disease: Analysis of randomized and excluded patients from the Coronary Artery Revascularization Prophylaxis (CARP) Trial. Circ, 116:640-640, 2007.
133. Garcia S, Ward HB, Moritz T, Littooy F, Goldman S, Pierpont G, Larsen G, **Reda D**, and McFalls EO. Perioperative cardiac events following vascular surgery are predicted by the Revised Cardiac Index but are not reduced in any risk sub-group by preoperative revascularization: Results from the Coronary Artery Revascularization Prophylaxis (CARP) Trial. Presented at the 57th annual scientific session of the American College of Cardiology, March 29-April 1, 2007, Chicago, IL. J Am Coll Cardiol, 51:A353-A353, 2008.
134. Garcia S, Hattler B, Moritz T, Goldman S, Shunk K, Littooy F, **Reda D**, Ward H, McFalls E. Coronary angiography is safe in patients with peripheral arterial disease: A sub-study of the coronary artery revascularization prophylaxis (CARP) trial. J Am Coll Cardiol, 51:B98-B98, 2008.
135. Broderick W, Campbell SC, Moritz T, Friedman N, Garewal H, Iyer P, Arcenas AG, Vanveldhuizen P, **Reda D**, Bhoopalam N. A phase III trial of zoledronic acid (Z) to prevent osteoporosis in men on early and prolonged androgen deprivation therapy (ADT) in a high risk VA population. Presented at the American Society of Clinical Oncologists (ASCO) Genitourinary (GU) Cancer Meeting, February 14 – 17, 2008 San Francisco, CA. J Urol, 179:252-252, 2008.
136. Pandya MB, Bhoopalam N, Moritz T, Friedman N, Garewal H, Iyer P, Vanveldhuizen P, Arcenas A, **Reda D**, Campbell S. A multicenter VA study of zoledronic acid in men on androgen deprivation therapy for prostate cancer with preexisting osteoporosis. Presented at the 2008 ASCO Genitourinary Cancers Symposium, February 2, 2008, San Francisco, CA.
137. Patel T, Hirter A, Kaufman J, Keithi-Reddy SR, **Reda D**, Singh A. Route of epoetin administration and hemoglobin variability in hemodialysis patients " Presented at the National Kidney Foundation annual meeting, April 2-5, 2008, Dallas, TX. Am J Kid Dis, 51:A78-A78, 2008.
138. Weaver, FM for the VA CSP 468/NINDS Study Group. Best medical therapy vs. deep brain stimulation for PD: Six month results from a multi-site randomized trial. Movement Disorders, 23:S197-198, 2008.
139. Weaver, FM for the VA CSP/468 NINDS Study Group. Adverse events following best medical therapy or deep brain stimulation for Parkinson's disease. Movement Disorders,

- 23:S220-220, 2008.
140. Pandya MB, Broderick W, Campbell SC, Garewal H, Friedman N, Moritz T, **Reda D**, Bhoopalam N. Recommendations for use of zoledronic acid (Z) for prevention and treatment of osteoporosis in men on androgen deprivation therapy (ADT) for prostate cancer (PC). Presented at the annual meeting of the American Society of Clinical Oncology, May 30 – June 3, 2008, Chicago, IL. J Clin Oncol, 26: May 20 suppl, abstr 16060, 2008.
 141. Florez, HJ; Moritz, T; Marks, J, **Reda D**, Warren S, Duckworth W, Abaira C. Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. Diabetologia, 61:S370-S370, 2008.
 142. Rinne SF, Mancil RM, Stelmack JR, Cummings RW, Mancil GL, Moran D, Ellis N, Tang C, **Reda DJ**, Stroupe K, Massof RW. Veterans Affairs Low Vision Intervention Trial Study Results and Therapy Curriculum. Presented at the AER International Conference, July 25, 2008, Chicago, IL.
 143. Bhoopalam N, Campbell SC, Iyer P, Arcenas AG, Vanveldhuizen P, Vera C, Terris M, Sharifi R, Garewal H, Wood P, Sadeghi-Nejad H, Steinbrenner L, Friedman N, Moritz T, **Reda D**. A phase III trial of zoledronic acid to prevent osteoporosis in men on early and prolonged androgen deprivation therapy in a high risk VA population. Presented at the 4th annual meeting of the Association of VA Hematology/Oncology, September 13, 2008, Nashville TN.
 144. Stelmack JP, Tang C, **Reda D**, Rinne S, Mancil R, Cummings RW, Stroupe K, Mancil GL, Massof R. The Veterans Affairs Low Vision Intervention Trial Follow-up: 12 Month Outcomes. Presented at the American Academy of Optometry meeting, October 23, 2008, Anaheim, CA.
 145. Kaafarani HM, Kaufman D, **Reda D**, Itani KM. Predictors of surgical site infection in laparoscopic and open ventral incisional herniorrhaphy. Presented at the Annual Academic Surgical Congress, February 3-5, 2010, San Antonio, TX. Abstract published in J Surg Res. 158(2):314, Feb 2010.
 146. Azad N, Agrawal L, Emanuele N, Klein R, Bahn G, Kaufman D, Moritz T, **Reda D**, Duckworth W, and Abaira C for the VADT Study Group. Intensive glycemic control (INT) and ocular outcomes in the Veterans Affairs Diabetes Trial (VADT). Presented at the American Diabetes Association 71st Scientific Sessions, June 24-28, 2011, San Diego CA. Abstract published in Diabetes, 60(7) Supp., July 2011.
 147. Chokrungvaranon N, Koska J, Bahn G, **Reda D**, Duckworth W, Abaira C and Reaven P for the VADT Study Group. Ability of indices of cardiovascular disease (CVD) risk and comorbidity to predict CVD outcomes with intensive glucose control in the VADT. Presented at the American Diabetes Association 71st Scientific Sessions, June 24-28, 2011, San Diego CA. Abstract published in Diabetes, 60(7) Supp., July 2011.
 148. Mc Neil RB and **Reda DJ**. Good practices and research reproducibility in the Department of Veterans Affairs (VA) Cooperative Studies Program. Presented at the Joint Statistical Meetings, August 2, 2011, Miami Beach, FL.
 149. Kapur K, Bhaumik D, Tang C, Hur K, Moritz T and Reda D. Sample size determination for longitudinal binary data. Presented at the Joint Statistical Meetings, August 4, 2011, Miami Beach, FL.
 150. Lai E, Monthaporn SB, Luo P, Follett K, Stern M, **Reda DJ**, Weaver FM. Falls in Parkinson's Disease. Presented at the 11th International Conference on Alzheimer's &

- Parkinson's Diseases, March 6-10, 2013, Florence, Italy
151. Katz M, San Luciano M, Luo P, Carlson K, Marks W, Larson P, Starr P, Follett K, Weaver FM, Stern M, **Reda DJ**, Ostrem J. Responsiveness of Parkinson's Disease motor subtypes to subthalamic nucleus (STN) Versus globus pallidus internus (GPi) deep brain stimulation (DBS): an additional analysis of the VA CSP #468 Study. Presented at the American Academy of Neurology 65th Annual Meeting, March 20, 2013, San Diego, CA. Abstract published on-line in Neurology 80(Meeting Abstract S23.006), 2013.
 152. Lai E, Monthaporn SB, Luo P, Follett K, Stern M, **Reda DJ**, Weaver FM. Risk of falls in Parkinson's Disease after deep brain stimulation. Presented at the American Academy of Neurology 65th Annual Meeting, March 20, 2013, San Diego, CA. Abstract published on-line in Neurology 80(Meeting Abstract P04.184), 2013.
 153. Fitzgibbons Jr. RJ, Ramanan B, Arya S, Turner SA, Dickhudt TJ, Li X, **Reda D**, and Gibbs J. Long-term results of a non-operative strategy (watchful waiting) for men with minimally symptomatic inguinal hernias. Presented at the American Surgical Association 133rd Annual Meeting, April 5, 2013, Indianapolis, IN.
 154. Marks WJ, Luo P, Lanier E, Patel U, Carlson K, Rothlind J, Galifianakis N, Sarwar A, Lai E, Ostrem J, Duda J, Bronstein J, Holloway K, Brodsky M, Chung K, Horn S, Snodgrass A, Harris C, Moy C, **Reda D**, Weaver F, Stern M, and Follett K. Long-term outcomes from the VA/NIH cooperative study on deep brain stimulation for Parkinson's Disease. Presented at the Movement Disorders Society 17th International Congress, Sydney Australia, June 16-20, 2013. Abstract published in Movement Disorders, 28 Suppl 1: 1280, 2013.
 155. Lai EC, Bryant MS, Luo P, Follett KA, Stern M, **Reda DJ**, Weaver FM. Risk of falls in Parkinson's Disease. Presented at the Movement Disorders Society 17th International Congress, Sydney Australia, June 16-20, 2013. Abstract published in Movement Disorders, 28 Suppl 1: 447, 2013.
 156. Saremi A, Bahn G, Ge L, Moritz T, Schwenke DC, Duckworth WC, Emanuele N, **Reda D**, Hayward R, Reaven PD FOR VADT Investigators. Intensive glucose-lowering therapy may reduce cardiovascular disease events in Hispanics in the Veterans Affairs Diabetes Trial (VADT). Presented at the American Diabetes Association 73rd Scientific Sessions, June 23, 2013, Chicago, IL. Abstract published in Diabetes, 62:A367, Meeting Abstract #1404-P, July 2013.
 157. Wolpaw JR, Bedlack RS, Ringer RJ, Reda DJ, Hill KJ, Banks PG, Vaughan TM, Shi H, Heckman SM, Carmack CS, Winden S, McCane LM, Ruff RJ. A clinical demonstration of EEG-based brain-computer interface (BCI): Long-term independent use of a P300-based BCI. Poster # 079.29/WW5. Presented at the Society for Neuroscience Meeting, November 9, 2013, San Diego, CA.
 158. Pape T, Rosenow J, Steiner M, Parrish T, Guernon A, Harton B, McNamee S, Patil V, Walker M, Froelich K, Burrell C, Odle C, Wang X, Herrold A, Zhao W, Reda D, Coneely M and Nemeth A. Therapeutic effect of familiar auditory sensory training for acute severe traumatic brain injury from a placebo-controlled trial. Abstract # 0144. Presented at the International Brain Injury Association 10th World Congress, March 20, 2014, San Francisco, CA. Abstract published in Brain Injury, 28:5-6, 566, (May) 2014.
 159. Bedlack R et al. A clinical demonstration of an EEG brain-computer interface (BCI) for ALS patients (VA Cooperative Study #567): enrollment, retention, and adherence.

- Presented at the American Academy of Neurology Annual Meeting, April 30, 2014, Philadelphia, PA. Abstract published in Neurology, 82(10):P4.086, April, 2014.
160. Sarwar AI, Carlson K, Luo P, Follett K, Stern M, Weaver FM, **Reda DJ**, Lai EC. For the CSP 468 Study. Gait and balance in Parkinson's disease (PD) following bilateral Subthalamic Nucleus (STN) and Globus Pallidus Interna (GPi) stimulation: 36 month follow-up of CSP#468 cohort. Presented at the 19th International Congress of Parkinson's Disease and Movement Disorders, June 14-18, 2014, San Diego, CA. Abstract published in Movement Disorders, 30:S237-238, Meeting Abstract 607, June, 2015.
 161. Florez H, Bahn G, Ge L, Reaven P, Valencia W, **Reda D**, Marks J, Emanuele N, Hayward R. Impact of glycemic control on quality of life in older adults with type 2 diabetes. Presented at the 2016 Annual Scientific Meeting of the American Geriatrics Society, May 19, 2016, Long Beach, CA. Abstract published in J Am Geriatrics Society, 64:S148, Meeting Abstract B168, May, 2016.
 162. Brawman-Mintzer O, Tang XC, Bizien M, **Reda D**, Harvey P, Arciniegas D, Horner MD, Wortzel H, Raskind M, Johnson-Greene L, Martineau RJ, Hamner M, Rodriguez-Suarez M, Jorge RE, McGarity S, Wei Y, Sindowski T, Donovan K. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury: A Double-Blind, Placebo-Controlled Multicenter Study (RiVET Trial). 55th Annual Meeting of the American College of Neuropsychopharmacology, December 5, 2016 in Hollywood, FL. Abstract published in Neuropsychopharmacology, Abstract M149, D41(suppl. 1):S116-S288, December 2016.
 163. Rothlind JC, York M, Carlson K, Luo P, Marks, Jr. WJ, Weaver FM, Stern M, Follett K, Duda J, Lai E, **Reda D**, for the CSP-468 study group. Predictors of multi-domain cognitive decline following deep brain stimulation surgery for treatment of Parkinson's Disease. Presented at the 45th annual meeting of the International Neuropsychological Society, New Orleans, LA February 3, 2017. Abstract published in J Int Neuropsych Society, pp. 237-238, June 12, 2017.
 164. Golier J, Flory J, **Reda D**, Li X, Robin L, Bizien M, Yehuda R, Baker D, Kimbrell T, Bechard B, Hurley R. Novel therapeutics in PTSD: A randomized clinical Trial of mifepristone. Presented at the 72nd Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, May 20, 2017. Abstract published in Biological Psychiatry, 81:10:279-280, May 15, 2017.
 165. Leehey DJ, Craig I, **Reda D**, Carlson K, Conner TA, Agarwal R, Kaufman JS, Anderson R, Huang GD, Emanuele N. Design of Pentoxifylline in Diabetic Kidney Disease (VA PTXRx). Presented at the American Society of Nephrology 2018 Meeting, October 27, 2018, San Francisco, CA. Abstract SA-PO154.
 166. Donovan JL, Davies L, Moghanaki D, Skinner V, Hwang S, Lynch T, Gierisch JM, Rooshenas L., Reda, D. Exploring the translation of the UK QRI (QuinteT Recruitment Intervention) to optimise recruitment to clinical trials in the US. Presented at the Society for Clinical Trials 40th Annual Meeting, May 21, 2019, New Orleans, LA.
 167. Banerjee S, Luo P, Reda DJ, Latif F, Hastings J, Abu-Fadel M, Bagai J, Baskar A, Kamath P, Lytal M, Lippe D, Scrymgeour A, Gleason T. Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or PREMIER Trial. Presented at the Society for Cardiovascular Angiography and Interventions 2019 Scientific Sessions, May 21, 2019, Las Vegas, NV.

168. Leehey DJ et al. Pentoxifylline in Diabetic Kidney Disease (VA PTXRx). Presented at ASN Kidney Week, Nov. 5-10, 2019 in Washington, DC, abstract published in JASN Abstract Supplement, PUB074, p1092.
169. Ostrem JL, Luo P, Weaver FM, Follett K, Galifianakis NB, Lai EC, Bronstein JM, Duda JE, Holloway K, Sarwar AL, Brodsky MA, Chung K, Spindler M, Marks Jr. WJ., Rothlind J, Snodgrass A, Moy C, **Reda DJ**, Huang G for the CSP 468F Study Group. 10 Year Clinical Outcomes of Subthalamic Nucleus versus Pallidal Deep Brain Stimulation for Parkinson's Disease: VA/NINDS CSP #468F. Presented at the AAN 2021 Annual Meeting, April 18, 2021, San Francisco, CA, abstract published in Neurology 96:15S: 4312, (April 13) 2021.